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Prion protein (PrP) is expressed on a wide variety of cells and plays an important
role in the pathogenesis of transmissible spongiform encephalopathies. However,
its normal function remains unclear. Mice that do not express PrP exhibit deficits
in spatial memory and abnormalities in excitatory neurotransmission suggestive
that PrP may function in the glutamatergic synapse. Here we show that transport
of D-aspartate, a non-metabolized L-glutamate analog, through excitatory amino
acid transporters (EAATs) was faster in astrocytes from PrP knockout (PrP KO)
mice than in astrocytes from C57BL/10SnJ wildtype (WT) mice. Experiments
using EAAT subtype-specific inhibitors demonstrated that in both WT and PrP
KO astrocytes, the majority of transport was mediated by EAAT1. Furthermore,
PrP KO astrocytes were more effective than WT astrocytes at alleviating Lglutamate-mediated excitotoxic damage in both WT and PrP KO neuronal
cultures. Thus, in this model, PrP KO astrocytes exerted a functional influence on
neuronal survival and may therefore influence regulation of glutamatergic
neurotransmission in vivo.
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CHAPTER ONE
INTRODUCTION
Prion protein (PrP) is expressed in several mammalian tissues and is
highly expressed in the central nervous system. While the precise function of PrP
is unknown, studies suggest that PrP plays a role in many aspects of
neurotransmission mediated by the neurotransmitter L-glutamate. Glutamatergic
neurotransmission is dependent on L-glutamate availability in the synaptic cleft
and subsequent activation of L-glutamate receptors. Specificity of activity is
regulated by excitatory amino acid transporters (EAATs) expressed on neurons
and astrocytes. The potential role PrP plays in neurotransmission and the pivotal
role of EAATs in controlling L-glutamatergic neurotransmission provided the
rationale to studying whether a function of PrP is to regulate concentrations of Lglutamate through modulation of EAAT activity.
1.1 Prion Protein
Prion Protein (PrP) is an evolutionarily conserved protein expressed in a
number of different species including fish, amphibians, birds, cervids, ungulates,
rodents and primates (Aguzzi et al., 2008). The gene encoding PrP is located on
chromosome 2 in mus musculus (Prnp) and chromosome 20 in homo sapiens
(PRNP). In some species, including bovine, deer, elk, mouse, rat and sheep, the
Prnp gene contains 3 exons, while in other species including hamsters and
humans, the gene contains 2 exons. Uniquely, the entire reading frame is
contained in one exon (Basler et al., 1986), which in mice is exon 3. Gene
expression is controlled by sequences contained in the 5’-flanking region, first
intron and 3’-untranslated sequences.
Similar to other membrane proteins, biosynthesis of PrP begins in the
rough ER and traffics through the Golgi to its final location on the plasma
membrane. In the rough ER, PrP is subject to post-translational modifications
including removal of its N-terminal signal peptide, addition of a C-terminal
glycosyl-phosphatidylinositol (GPI) anchor, addition of N-linked glycosylations
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and formation of a disulfide bond. PrP then passes through the Golgi for further
modifications before reaching the plasma membrane where it exists as a double
glycosylated protein anchored to the plasma membrane in detergent- resistant
lipid rafts via the GPI anchor.
PrP exists as a disordered amino terminal flexible domain (amino acid
residues 23-124) and globular carboxyl terminal domain (amino acid residues
125-226). The N-terminal domain contains a highly conserved octapeptide repeat
region that is able to bind copper with µM affinity. The C-terminal domain
contains three alpha helices (amino acid residues 144-154, 173-194 and 200220) and an anti-parallel beta sheet formed by beta strands 128-131 and 161164. A disulfide bond links cysteine residues 179 and 214.

Figure 1.1 Prion Protein. a) NMR solution structure of elk PrP residues 121-231 (adapted from
(Gossert et al., 2005)).

While the majority of PrP molecules are at the cell surface, a pool are
constitutively cycling between the plasma membrane and endocytic
compartments. Surface iodination of PrP revealed that a population of PrP
molecules cycle between the plasma membrane and endocytic compartments
with a transit time of 60 minutes (Shyng et al., 1993). However the mechanism
of endocytosis is controversial. Immunogold EM revealed PrP enriched in
caveolae at the plasma membrane of CHO cells (Peters et al., 2003) suggesting
2

a mechanism involving a caveolae-mediated endosomal pathway. However,
stronger evidence exists suggesting PrP endocytosis is clathrin-mediated, which
is unusual for GPI anchored proteins that lack an intracellular sequence
necessary for interaction with endocytic adaptor proteins. Electron microscopy
revealing PrP in clathrin-coated vesicles, prevention of internalization by
disrupting clathrin lattices (Shyng et al., 1994) and studies using cells transfected
with dynamin mutant K44A (Magalhaes et al., 2002) strongly suggest clathrin is
involved in endocytosis. Internalization of GPI anchored PrP may involve usage
of its positively charged domain (KKRPKP) in the amino terminal region to
interact with the extracellular region of an integral membrane protein that also
contains a localization signal in its cytoplasmic domain for clathrin-mediated
endocytosis.
While GPI anchored proteins have many diverse functions, a definitive
understanding of the physiological function of PrP is still unknown. With the
intent of understanding the function of PrP, two independent lines of PrP
knockout mice were generated. The lines differed in the strategy used to disrupt
Prnp gene expression: in Zurich PrP0/0 mice, a portion of exon 3 of the Prnp gene
was replaced with a neomycin phosphotransferase (neo) gene (Bueler et al.,
1992) and in Edinburgh PrP-/- mice, a neo gene was inserted into exon 3 of the
Prnp gene (Manson et al., 1994). In both lines of mice, there was a lack of overt
disturbances in development or behavior (Bueler et al., 1992; Manson et al.,
1994). Though PrP KO mice did not obviously suggest a function for PrP, they
did provide definitive evidence that expression of PrP was necessary for
productive infection with transmissible spongiform encephalopathies (Bueler et
al., 1993; Sailer et al., 1994).
Further examination of PrP knockout mice revealed several subtle
abnormalities suggestive of varied physiological functions (Table 1). However,
many of the functional studies compared PrP KO mice to PrP expressing mice
with different genetic backgrounds. Both Zurich PrP0/0 and Edinburgh PrP-/- mice
were constructed using a sub-strain of 129 embryonic stem cells. However, to
maintain the PrP knockout phenotype, many subsequent lines were crossed to
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different strains of mice resulting in a mixed background. Thus, in several
studies, the possibility exists that the phenotype is a result of other genes whose
alleles differ between the knockout and wild-type mice compared. The only
studies to compare mice of the same genetic background (Edinburgh PrP-/versus 129/Ola mice) demonstrated PrP KO mice to have an abnormal quantity
and morphology of mitochondria (Miele et al., 2002), altered regulation of amyloid
beta production in the brain (Parkin et al., 2007), altered oxidative homeostasis in
the brain (Wong et al., 2001) and an inability to induce long term potentiation
(LTP) in the hippocampus (Manson et al., 1995).
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Phenotype of PrP KO
mice1

Implied Function
of PrP

Background Strains of
Mice Compared 2,3
-/-

Did not have LTP deficits
when exposed to amyloid-β
oligomers

Amyloid-β oligomer
receptor

PrP bc C57BL.6 vs. C57
BL/6
0/0
PrP hybrid vs. C57BL6
“hybrid”

Chronic demylenating
5
polyneuropathy

Myelin maintenance

PrP

Maintaining neuronal
homeostasis

PrP bc C57BL/6 vs.
C57BL/6

Iron uptake and
transport

PrP

Control of metastasis
formation

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

Late T-cell activation
antigen

PrP

Increased susceptibility to
kainate induced seizures
Altered expression of
glutamate and GABA
receptor subunits
Inefficient iron transport.
Decreased iron content in
red blood cells
Increased lung colonization of
0/0
immortalized PrP
mesenchymal embryonic
cells
Reduced induction of Thelper cell cytokines
Poor control of autoimmune
and infectious diseases
Reduced olfactory detection
Reduced paired pulse
plasticity at dendrodendritic
5
synapses
Increased anxiety and poor
performance in social
recognition asks following
brain injury influencing
cortical development
Slower rate of astrocyte
maturation
Reduced neuritogenesis
Delayed feedback inhibition
of hypothalamic-pituitaryadrenal (HPA) axis following
acute stress
Abnormal functioning and
lack of LTP formation in
cerebellar granule cells
Poor performance in motor
control tasks
Decreased defense
responses when confronted
with coral snakes
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Influences
processing of
sensory information
by the olfactory
system
Aids in recovery
following brain injury
Influences cortical
development relating
to short term memory
Receptor for stress
inducible protein
Mediates astrocyte
development
Modulates neuronglia crosstalk
Regulation of HPA
axis

0/0

bc Balb/c vs. Balb/c

0/0

0/0

bc FVB vs. FVB

0/0

Citation
Lauren et al.,
2009
Balducci et
4
al., 2010
Bremer et al.,

Rangel et al.,
2009

Singh et al.,
2009
Muras et al.,
2009

bc FVB/N vs. FVB/N

Ingram et al.,
2009

PrP mixed vs. F1 (129/Sv
X C57BL/6J)
-/PrP vs. 129/Ola

Le Pichon et
al., 2009

0/0

0/0

0/0

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

0/0

PrP mixed vs. F1 (129/Sv
X C57BL/6J)
-/PrP bc C57BL/10 vs.,
wt/wt
Prnp

-/-

PrP vs. 129/Ola

Xikota et al.,
2008
Arantes et al.,
2009
Caetano et
al., 2008
Lima et al.,
2007
SanchezAlavez et al.,
2008

0/0

PrP mixed vs. F2
(129S1/SvImJ X C57BL/6J)

Granule cell
development
Modulation of innate
fear and panic
related behaviors

5

0/0

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

Prestori et al.,
2008

Lobao-Soares
et al., 2008

Phenotype of PrP KO
mice1
Higher activity of neutral and
acid sphingomyelinase
Increased and prolonged
NMDA evoked currents in
hippocampal neurons
Increased susceptibility to
NMDA mediated neuronal
death
Decreased infiltration of
inflammatory cells and
activated microglia following
encephalomyocarditis virus
infection
Increased neuronal apoptosis
Weaker
afterhyperpolarizations in
cererbellar and hippocampal
neurons due to stronger
calcium buffering and
extrusion rates
Increased mitochondrial
respiration and free radical
production
Defects in mitochondrial
morphology
Altered superoxide dismutase
activities

Implied Function
of PrP

Background Strains of
Mice Compared 2,3

Regulation of
sphingolipid
associated signaling

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

Inhibitor of NR2D
subunit of NMDA
receptor

Littermates of PrP
or FVB)

Role in induction of
inflammation and
inhibitor of apoptosis

PrP mixed vs. F1 (Prnp
0/+
X Prnp )

Role in neuronal
calcium homeostasis

PrP

0/0

0/0

X 129

0/0

0/+

0/0

bc FVB/N vs. FVB/N

Protection against
oxidative stress

PrP vs. 129/Ola

Altered dorsal root ganglion
axonal growth (substrate
dependent)

Interacts with
vitronectin

PrP mixed vs. F1 (129/Sv
X C57BL/6J)
-/PrP bc C57BL/10 vs.,
wt/wt
Prnp

Resistant to thermal and
visceral inflammatory
nociception

Role in nocicpetive
transmission
mediated by
inflammation

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

2+

Decreased [Ca ] I levels
Decreased neuronal viability
to H2O2
Higher percentage of CD8
spleen dendritic cells
2+

+

-/-

Citation
Schmalzbauer
et al., 2008

Khosravani et
al., 2008

NasuNishimura et
al., 2008

Powell et al.,
2008

Paterson et
al., 2008
Lobao-Soares
4
et al., 2005

0/0

0/0

Influences
development of CD8
dendritic cells

0/0

Martínez del
Hoyo G, 2006
Fuhrmann et
al., 2006

Ca homeostasis

Littermates of C57Bl6 x
129Sv Prnp+/- mice

Reduced allogenic T Cell
response

Role in
immunological
synapse between
dendritic cells and T
cells

PrP bc C57BL/6 vs.
C57Bl/6
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Krebs et al.,
2007

PrP bc C57BL/6 vs.
C57Bl/6

Decreased Ca influx via L2+
type voltage gated Ca
channels

2+

Meotti et al.,
2007

0/0

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

H2O2 sensor

Hajj et al.,
2007

0/0

Ballerini et al.,
2006

Phenotype of PrP KO
mice1
Increased infarct volume
following transient or
permanent ischemia
Reduced Akt activation
Enhanced caspase 3
activation
Delay in neural differentiation
Impaired self renewal of
hematopoietic stem cells
Arrested NCAM dependent
neurite outgrowth
Impaired hippocampal
dependent spatial learning
Impaired LTP in dentate gyrus
Reduced copper content in
synaptosomes

Implied Function
of PrP

Background Strains of
Mice Compared 2,3

Citation

0/0

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

Anti-apoptotic

Role in neurogenesis
and adult neural
development
Supports self renewal
of hematopoietic
stem cells
Nervous system
development using
NCAM as a signaling
receptor
Regulator of
glutamatergic
signaling
Regulates copper
concentrations in
synaptosomes

-/-

PrP bc C57BL.6 vs. C57
BL/6

Steele et al.,
2006

-/-

PrP bc four or six times to
C57 BL/6J CD45.2 vs.
CD45.2 C57BL/6
0/0

PrP bc C57BL/6 vs.
C57Bl/6

Zhang et al.,
2006
Santuccione
et al., 2005

-/-

PrP bc two times to
C57BL.6 vs. C57 BL/6
-/PrP vs. 129/Ola
0/0

PrP hybrid vs. C57BL6
and 129 “hybrid”

Increased male susceptibility
to ischemia

Neuroprotection
against ischemia

Decreased anxiety and
locomotion in response to
acute stress
Increased infarct size (200%
after ischemia, increased
Erk1/2, STAT I and caspase 3

Modulation of anxiety
and muscle activity in
response to stress

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

Neuroprotective, antiapoptotic

PrP mixed vs. F1 (129/Sv
X C57BL/6J)

1

Weise et al.,
2006

PrP

0/0

hybrid vs. C57BL/6

0/0

0/0

Criado et al.,
5
2005
Giese et al.,
2005
SakuraiYamashita et
al., 2005
Nico et al.,
2005
Spudich et al.,
2005

Phenotype of PrP KO mice or primary cells harvested from PrP KO mice
0/0
-/PrP = Zurich PrP KO mice on a mixed background. PrP = Edinburgh PrP KO mice on a 129/Ola
background
3
bc = backcross to the wild-type strain (as indicated) for at least eight generations
4
Disputed results or conclusions of the study
5
Phenotypic rescue in PrP expressing transgenic lines of mice
2
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A number of studies, albeit using mice of different backgrounds, have also
reported synaptic abnormalities relating to L-glutamatergic neurotransmission.
PrP KO mice suffer from deficits in hippocampal spatial memory (Criado et al.,
2005), have abnormal responses to NMDA receptor antagonist MK-801(Coitinho
et al., 2002) and exhibit reduced excitatory post-synaptic potentials (Carleton et
al., 2001) and afterhyperpolarization potentials (Mallucci et al., 2002). Decreased
levels of LTP in PrP KO mice has been rescued by expression either of human
PrP (Whittington et al., 1995; Asante et al., 2004) or by neuronal expression of
mouse PrP (Criado et al., 2005). Primary neurons cultured from PrP KO mice
exhibit increased NMDA receptor activation and an increased vulnerability to
NMDA mediated excitotoxicity (Khosravani et al., 2008). Collectively, these
observations suggest that PrP KO mice suffer from deficits in neurotransmission,
consistent with attenuated glutamate signaling, which could result from excessive
clearance of L-glutamate from the synaptic space.

1.2 The Glutamatergic System
L-glutamate is the primary excitatory neurotransmitter in the mammalian
nervous system, mediating neuronal communication that includes fast synaptic
transmission and higher order processing necessary for development and
learning and memory. L-glutamate is sequestered intracellularly maintaining an
intracellular-extracellular concentration gradient of several million-fold (Zerangue
and Kavanaugh, 1996; Herman and Jahr, 2007). Thus, preserving homeostatic
levels of L-glutamate is important in maintaining specificity of signaling and
appropriate receptor activation.
The highest concentration of L-glutamate in the CNS is found in nerve
terminals (Ottersen et al., 1992) . Here, L-glutamate is packaged into synaptic
vesicles by proton-dependent vesicular transporter, V-GLUT. Once an action
potential reaches the nerve terminal, vesicles loaded with L-glutamate fuse with
the plasma membrane and release their contents extracellularly. In the synaptic
space, L-glutamate can activate G-protein coupled metabotropic L-glutamate
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receptors and ionotropic L-glutamate receptors. Diffusion of L-glutamate also
permits activation of receptors extrasynaptically.
Metabotropic L-glutamate receptors are G-protein coupled receptors
whose activation play a modulatory role by regulating the production of
intracellular messengers and consequently activating or inhibiting second
messenger systems. The receptors belong to Class C G-protein coupled
receptors, characterized by 7 transmembrane helices connected by 3
intracellular and 3 extracellular loops. To date, there have been 8 metabotropic
glutamate receptors cloned that are divided into 3 groups. Group I includes
mGlu1 and mGlu5 that are localized post-synaptically on neurons and who are
coupled to phosplipase C. Group II includes mGlu2 and mGlu3, found both preand post-synaptically and are negatively coupled to adenylyl cyclase. Group III
includes mGlu4, mGlu6, mGlu7 and mGlu8 that are localized pre-synaptically.
The synaptic location of these receptors allows them to modulate both
neurotransmitter release and regulation of fast acting ionotropic L-glutamate
receptors.
Fast-acting ionotropic L-glutamate receptors are L-glutamate gated ion
channels that permit an influx of sodium and/or calcium from the extracellular
environment to the inside of the cell. Binding of L-glutamate to low affinity AMPA
or Kainate receptors (who also preferentially bind AMPA and kainate,
respectively) causes an influx of sodium, which serves to depolarize the cell. In
contrast, the high affinity NMDA receptor acts as a coincidence detector,
requiring glycine and L-glutamate binding, as well as previous depolarization of
the membrane in order to permit the entrance of sodium and calcium into the cell.
Compared to AMPA and kainate receptors, NMDA receptors have slow
deactivation times and are critical in mediating higher order processing.
Several distinct subtype compositions have been identified differing in
their sensitivities to pharmacological agents, their channel opening times, their
distribution in the brain and their relative concentrations during development.
Most NMDA receptors are heteromeric molecules consisting of two obligatory
NR1 subunits and two NR2 subunits. Four isoforms of the NR2 subunit have
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been identified, NR2A, NR2B, NR2C and NR2D. These isoforms are distinct in
determining characteristics of the NMDA receptor, which influence channel
kinetics. The type of NR2 subunit present determines deactivation times of the
receptor in response to L-glutamate. The deactivation times span a 50-fold range
with NR2A subunits deactivating fastest and NR2D subunits slowest (NR2A >
NR2C = NR2B >> NR2D). NMDA receptor subunit composition and subsequent
receptor deactivation kinetics reflect the nature of the synapse in which they are
expressed. NR2A containing receptors are present at most mature synapses
while NR2B containing receptors are expressed predominantly during
development. The changes in the molecular makeup of NMDARs are part of
what defines the “critical period” during development in which neuronal circuits
are fine tuned (Cull-Candy and Leszkiewicz, 2004).
L-glutamate is the major excitatory neurotransmitter in the CNS and as
such, extracellular levels of L-glutamate must be tightly controlled to maintain
specificity of signaling. Depending on the location of the synapse, L-glutamate
signaling has various functions throughout the CNS such as mediating
experience dependent synaptic plasticity through the phenomena of long-term
potentiation (LTP) and long-term depression (LTD), development and fine-tuning
of excitatory synapses, the perception of pain and modulation of signaling by
other neurotransmitters such as dopamine. The concentration of L-glutamate in
the extracellular space and the amount of time it remains in the space
determines the number of L-glutamate receptors activated. Therefore, keeping
extracellular concentrations of L-glutamate low allows for a high signal-to-noise
ratio in synaptic and extrasynaptic transmission (Danbolt 2001).
Furthermore, keeping the extracellular concentration of L-glutamate low
prevents neuronal death. Excessive activation of L-glutamate receptors and
prolonged excitatory synaptic transmission can lead to neuronal death through
excitotoxicity (Olney 1996). L-glutamate mediated excitotoxicity is mediated by a
sustained activation of L-glutamate receptors. Because of its high permeability to
calcium, the NMDA receptor in particular mediates the majority of excitotoxic
insult although AMPA and Kainate receptors play a role in sustained
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depolarization of neurons (Salinska et al., 2005; Waxman and Lynch 2005). The
molecular events leading to neuronal death are unclear although altered calcium
homeostasis plays a distinctive role in dysregulation of signal transduction
pathways, activation of calcium dependent calpains (Wu et al., 2004), and
activation of metabolic pathways that generate free radicals (Salinska et al.,
2005). Neuronal death follows excitotoxicity and therapeutic strategies aimed
against excitotoxcity are hoped to delay pathogenesis of many neurodegerative
diseases.
Thus, maintaining basal concentrations of L-glutamate is critical in
maintaining signal specificity and preventing neuronal death. Levels of Lglutamate following vesicular release are believed to reach millimolar levels
during excitatory transmission (Clements 1992) but must be rapidly cleared to
markedly lower (0.1-1µM) homeostatic levels (Herman and Jahr 2007).
Extracellular L-glutamate concentrations are regulated by the activity of
excitatory amino acid transporters present on neurons and astrocytes.
1.3 Excitatory Amino Acid Transporters
Unlike other neurotransmitters, such as acetylcholine whose extracellular
concentrations are controlled by enzymatic degradation, rapid termination of Lglutamate signaling is achieved by cellular uptake. The majority of L-glutamate
transport is mediated by high affinity, Na+ dependent excitatory amino acid
transporters (EAATs). To date, five EAAT subtypes with high affinity for Lglutamate have been identified. EAAT1 (GLAST) and EAAT2 (GLT-1) are
primarily glial transporters responsible for the bulk of L-glutamate clearance.
EAAT3 (EAAC), EAAT4 and EAAT5 are expressed by neurons.
Levels of transporter subtypes are regionally, developmentally and functionally
specific.
Characterization of the EAATs was aided by molecular pharmacology,
used to both distinguish between subtypes and understand the transport
process. Experiments aimed at understanding basic amino acid substrate
selectivity identified D-aspartate as an inhibitor of L-glutamate uptake and
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excellent alternate substrate with a Km in glial cultures of 60-80µM compared to
L-glutamate whose Km is 30-90µM (reviewed in Bridges et al., 1999). One of the
earliest competitive inhibitors characterized, effective at all five EAATs and a
substrate of EAAT1-4, was B-threo-hydroxyaspartate (ß-THA). Subsequently, ßTHA has been used as a backbone for the development of other EAAT inhibitors
incuding ß-threo-benzyloxyaspartate (TBOA), a non-substrate pan-EAAT
inhibitor with Ki values in the 1-10µM range.
To date, the majority of inhibitors exhibiting a high degree of selectivity for
one transporter subtype over the others are limited to EAAT2. Potent inhibitors of
EAAT2 include the classic inhibitor dihydrokainate (DHK, Ki = 23µM) and, more
recently, WAY213613 (IC50 = 85nM) (Bridges et al., 1999; Dunlop et al., 2005).
Alternate substrates at EAAT1, 4-MG and L-serine-O-sulfate can be used to
distinguish EAAT 1 from EAAT2 activity. Recently, a selective EAAT1 inhibitor,
UCPH 101, has been developed (Jensen et al., 2009). The usage of
pharmacology, either through subtype selective inhibitors or through subtype
specific alternate substrates, has allowed understanding the delineation of
subtype-specific roles in the transport of L-glutamate.
Glial transporters, EAAT1 and EAAT2 are expressed throughout the
mature CNS and are responsible for the majority of L-glutamate clearance.
However, there is developmental and regional enrichment of one subtype over
the other. During development, EAAT1 is the dominant transporter expressed
and functional though protein levels of both transporters increase dramatically
during synaptogenesis (Shibata et al., 1996; Sutherland et al., 1996). In the adult
however, EAAT1 expression and function dominates in Bergmann glia of the
cerebellum. In other regions of the brain, EAAT2 is the major glutamate
transporter functional though EAAT1 expression remains high (Danbolt, 2001).
Whether the same astrocyte expresses both EAAT1 and EAAT2 is controversial;
immunogold labeling demonstrated co-expression (Haugeto et al., 1996) while
analysis of promoter activity demonstrated a non-overlapping pattern of
expression (Regan et al., 2007). The importance of the relative stoichiometry of
one subtype over the other in a single astrocyte or region is unknown. EAAT2
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knockout mice do suffer from lethal spontaneous seizures (Tanaka et al., 1997).
However, levels of neuronal death following selective pharmacological
inactivation of EAAT2 in adult mice did not mirror that when all glutamate
transporters were rendered inactive (Selkirk et al., 2005), suggesting that
following stress, EAAT1 can rapidly be mobilized for dominant function.
In contrast to glial L-glutamate transporters, neuronal transporters are
considered to make a minor contribution to overall L-glutamate clearance.
EAAT3 expression is highest in the hippocampus, cerebellum, basal ganglia,
forebrain and spinal cord. EAAT4 expression is highest on Purkinje neurons in
the cerebellum and EAAT5 expression is limited to the retina. EAAT3 and EAAT4
are expressed postsynaptically and are though to provide L-glutamate as a
precursor for GABA synthesis (Sepkuty et al., 2002).

Figure 1.2 The Glutamatergic Synapse.
Following an action potential in the presynaptic neuron, L-glutamate vesicles fuse with the plasma
membrane and release L-glutamate into the synaptic cleft. L-glutamate can bind to and activate
NMDA, AMPA, Kainate and metabotropic L-glutamate receptors causing fast or long-lasting
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changes in the activated neuron. The L-glutamate signal is terminated by transport of L-glutamate
into astrocytes by EAAT1 and EAAT2. L-glutamate is then rapidly synthesized into glutamine
(Gln) by glutamine synthetase. L-Glutamate is also transported by EAAT3 and Xct. EAAT 3 is
localized to neurons and provides L- glutamate for GABA synthesis. System Xct, localized to
astrocytes, exchanges glutamate for cysteine, which is subsequently used for gluthathione
synthesis. PrP is expressed on astrocytes and neurons in the synapse.

The EAATs are defined as symporters, transporting the substrate by cotransport and counter-transport of ions (Bunch et al., 2009). The overall goal of
transport is to accumulate L-glutamate intracellularly against its concentration
gradient. This is powered by the co-transport of 3 Na+ ions and one H+ ion.
Following release of co-transported L-glutamate and ions, one K+ ion is countertransported and released to the extracellular space (Zerangue and Kavanaugh,
1996). The EAATs also conduct a thermodynamically uncoupled Cl- flux, thereby
acting as a Cl- channel (Wadiche et al., 1995a).
The transport cycle occurs by an alternating access mechanism
(Kavanaugh, 1998; Yernool et al., 2004) or cow chute mechanism (personal
communication, Terri Mavencamp) in which two major conformations of the
EAATs are employed. The first conformation is an outward conformation where
the substrate-binding site faces the synaptic space. The second conformation is
inward, allowing the substrate-binding site to be accessible to the cytoplasm of
the cell. The full cycle of transport begins with binding of the co-transported ions
(3 Na+, 1 H+) and substrate to the transporter in the outward conformation. This
leads to translocation of the transporter resulting in an inwards conformation. The
co-transported ions and substrate are released and intracellular K+ binds.
Consequently, the substrate binding site reorients to the outside (Tzingounis and
Wadiche, 2007). Possibly due to the steps required sequester L-glutamate
intracellulary, the full cycle is relatively slow, estimated to be between 60-80ms
(Wadiche et al., 1995b). Reconciling the slow transport cycle with the mM
amounts of L-glutamate present in the synaptic cleft during vesicular release
suggest that the EAATs initially function as L-glutamate buffers, terminating
excitatory signaling by trapping L-glutamate (Diamond et al., 1997).
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Much of the structure of the EAATs has been inferred following the
elucidation of the crystal structure of a bacterial orthologue of the EAATs, a
sodium-dependent Asp transporter from Pyrococcus horikoshii, GltPh (Yernool et
al., 2004). The membrane transporter is composed of a bowl shaped homomer
with three independent subunits. Each subunit of the trimer is capable of a
transport cycle. The monomer contains an intercellular N and C termini, eight
transmembrane (TM) regions and two hairpin loops. The glutamate binding site is
at the bottom of the bowl, between the 2 hairpin loops, which are hypothesized to
act as gates to the binding site (Boudker et al., 2007). The EAATs are
glycosylated in the hydrophilic loop between TM 3 and TM4 although the number
of glycosylations in the region differ among the EAAT subtypes (Seal and Amara,
1999).
The overall purpose of the EAATs is to maintain homeostatic levels of Lglutamate. Too much L-glutamate can lead to neuronal death through initiation of
excitotoxic cascades. The impact of glial protection from L-glutamate mediated
excitotoxicity through EAAT activity has been demonstrated in primary cultures
altering glia/neuron ratios and by pharmacological blockade of the EAATs
(Rosenberg and Aizenman, 1989; Robinson et al., 1993; Rothstein et al., 1996).
Several neurodegenerative diseases have implicated low EAAT activity as
contributing to pathology, including amyotrophic lateral sclerosis (ALS) (Rothstein
et al., 1992), HIV-associated dementia (Sardar et al., 1999), and Alzheimer’s
Disease (Masliah et al., 1996). Thus, increasing activity has been a therapeutic
target. In a mouse model of ALS, increased EAAT expression through
administration of β-lactam antibiotics delayed neuronal loss (Rothstein et al.,
2005). However, high EAAT activity can also decrease the amount of synaptic Lglutamate necessary for proper L-glutamatergic neurotransmission. Elevated Lglutamate transport has led to decreased LTP in the hippocampus (Filosa et al.,
2009) and impaired hippocampal dependent learning (Carmona et al., 2009).
Hyperactive EAAT activity might contribute to reduced L-glutamatergic signaling
observed in schizophrenia (Miyamoto et al., 2005). Thus, the EAATs play a
powerful role in carefully regulating activation of L-glutamate receptors, ensuring
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enough L-glutamate can be present for signaling without having too much to
initiate excitotoxic pathways. Dysfunction in EAAT activity may be one of the
causes of disease in Transmissible Spongiform Encephalopathies.
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Abstract
Prion protein (PrP) is expressed on a wide variety of cells and plays an important
role in the pathogenesis of transmissible spongiform encephalopathies. However,
its normal function remains unclear. Mice that do not express PrP exhibit deficits
in spatial memory and abnormalities in excitatory neurotransmission suggestive
that PrP may function in the glutamatergic synapse. Here we show that transport
of D-aspartate, a non-metabolized L-glutamate analog, through excitatory amino
acid transporters (EAATs) was faster in astrocytes from PrP knockout (PrP KO)
mice than in astrocytes from C57BL/10SnJ wildtype (WT) mice. Experiments
using EAAT subtype-specific inhibitors demonstrated that in both WT and PrP
KO astrocytes, the majority of transport was mediated by EAAT1. Furthermore,
PrP KO astrocytes were more effective than WT astrocytes at alleviating Lglutamate-mediated excitotoxic damage in both WT and PrP KO neuronal
cultures. Thus, in this model, PrP KO astrocytes exerted a functional influence on
neuronal survival and may therefore influence regulation of glutamatergic
neurotransmission in vivo.
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Introduction
Prion protein (PrP) is an evolutionarily conserved,
glycophosphatidylinositol-anchored membrane protein expressed in the
mammalian nervous system, as well as in many other tissues. Expression in the
CNS begins early in development and remains throughout adulthood (Miele et
al., 2003). Despite its wide expression, the function of PrP remains enigmatic.
While PrP knockout mice (PrP KO) do not suffer from overt disturbances in
development or behavior (Bueler et al., 1992; Manson et al., 1994), they do
exhibit subtle abnormalities which suggest PrP involvement in various cellular
processes including neuroprotection against oxidative stress, support for neurite
outgrowth, and maintenance of myelinated axons (reviewed in Aguzzi et al.,
2008). In particular, PrP KO mice suffer from deficits in hippocampal spatial
memory (Criado et al., 2005) and NMDA receptor-related neurophysiological and
behavioral abnormalities, suggestive of a function of PrP within the glutamatergic
synapse (Collinge et al., 1994; Manson et al., 1994; Carleton et al., 2001;
Mallucci et al., 2002; Criado et al., 2005; Khosravani et al., 2008). These
dysfunctions in PrP KO mice could be attributable to a variety of underlying
mechanisms involving aberrant signaling through glutamate receptors on
neurons and/or abnormal neurotransmitter regulation by glutamate transporters
on astrocytes.
One of the major functions of astrocytes is to sequester the excitatory
neurotransmitter L-glutamate intracellularly and thereby regulate activation of
excitatory amino acid receptors (Anderson and Swanson, 2000; Bridges and
Esslinger, 2005; Eulenburg and Gomeza, 2010). Clearance of L-glutamate is
primarily mediated by high affinity, sodium-dependent excitatory amino acid
transporters (EAATs). Two of the five identified transporter isoforms, EAAT1 and
EAAT2, are highly expressed on astrocytes in the cerebellum, hippocampus and
cerebral cortex. Both transporters are located on glial plasma membranes in
close apposition to the neuropil and, in combination, are responsible for the bulk
of L-glutamate transport in the CNS (Danbolt, 2001). The EAATs play a pivotal
role in controlling excitatory signaling as highlighted both by their anatomical
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specificity (Anderson and Swanson, 2000) and ability to protect neurons from
glutamate-mediated excitotoxicity (Robinson et al., 1993; Rothstein et al., 1996).
An inability of astrocytes to regulate L-glutamate neurotransmission might
lead to deficits in excitatory neurotransmission and, in particular may contribute
to deficits observed in PrP KO mice. In the present experiments, we carried out
detailed kinetic studies on EAAT-mediated glutamate transport in astrocytes
prepared from C57BL/10SnJ wildtype (WT) mice and from PrP KO mice
containing 98.5% sequence identity to the C57BL/10SnJ genotype. We found
that astrocytes from PrP KO mice exhibited higher rates of sodium dependent
transport of the EAAT-selective substrate D-aspartate than did astrocytes from
WT PrP expressing mice. Using inhibitors selective for EAAT subtypes, we
examined the type of transporters functional in both PrP KO and WT astrocytes
and investigated whether PrP related changes in activity could influence neuronal
vulnerability to glutamate-mediated excitotoxicity. These results provide a
potential explanation for the behavioral abnormalities observed in PrP KO mice.
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Materials and Methods
Animals.
C57BL/10SnJ mice (WT) were purchased from Jackson Labs (Bar Harbor,
ME). Homozygous PrP null (PrP KO) mice on the 129/Ola background (Manson
et al., 1994) were backcrossed nine times to C57BL/10SnJ mice selecting for the
PrP KO allele by PCR identification at each cross (Race et al., 2009). Single
nucleotide polymorphism (SNP) analysis was performed on DNA from PrP KO
mice, and results were compared to DNA from C57BL/10SnJ mice (Taconic
Farms Inc., Rensselaer, NY). Non-C57BL/10SnJ SNPs, i.e. from the 129/Ola
mouse strain donor of the knockout Prnp gene, were identified only on
chromosome 2, adjacent to the Prnp gene locus.
Astrocyte and Neuron Cell Cultures.
Mixed glial cells were harvested from the cortices of WT and KO 1-2 day
old mice using modifications of the method of McCarthy and de Vellis (McCarthy
and de Vellis, 1980). Cortices, with meninges removed, were triturated, plated in
T-25 flasks with DMEM/F12 (Invitrogen, Carlsbad, CA) containing 15% fetal
bovine serum (HyClone, Omaha, NE) and maintained in a 5% CO2 incubator at
37°C. Approximately seven days later, when cultures were confluent, microglia
and oligodendrocytes were removed from the astrocyte cultures by orbital
shaking (overnight, 250 rpm). Purified astrocyte cultures were harvested with
trypsin. For D-aspartate uptake assays, astrocytes were reseeded at 1 x 105
cells/well in 12 well plates and maintained with fresh media every three days. In
some experiments, astrocytes were assayed seven days post-seeding, upon
reaching confluence. In other experiments, confluent cultures were treated with
0.25mM dibutyryl cyclic AMP (dbcAMP) (Sigma Aldrich, St. Louis, MO) for an
additional ten days with media changes including dbcAMP every three days. The
inclusion of dbcAMP induces biochemical and morphological changes more
representative of astrocytes in vivo including greater EAAT expression (Schlag et
al., 1998). Consistent with other reports (Schlag et al., 1998), we found that
treatment with dbcAMP significantly increased EAAT1 and EAAT2 expression as
judged by analysis of mRNA by quantitative PCR (Figure 3).
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Primary cortical neurons were prepared essentially as described by Kaech
and Banker (Kaech and Banker, 2006). Briefly, whole cerebral neocortices
removed from either WT or PrP KO embryos (14-16 days gestation) were
digested for 30 minutes with 0.25% trypsin (Invitrogen, Carlsbad, CA) and
washed four times in Hanks Balanced Salt Solution (HBSS) (Invitrogen,
Carlsbad, CA). Cells, 5 x 104 cells/well, were plated onto a bed of 2.5 x 104
purified astrocytes that had been plated in 24 well plates two days earlier.
Neuron cultures were initially seeded in MEM with 10% heat - inactivated horse
serum (HyClone, Omaha, NE) and 0.25% glucose. The media was completely
replaced 6 hours later with Neurobasal media (500µl) (Invitrogen, Carlsbad, CA)
supplemented with Glutamax (Invitrogen, Carlsbad, CA), B-27 with antioxidants
(Invitrogen, Carlsbad, CA) and 5µM cytosine arabinoside (Sigma Aldrich, St.
Louis, MO) to halt cell proliferation. Cells were fed once at day 7 by replacing half
the media with fresh media. Neuronal cultures were used 14 days later,
coinciding with NMDA receptor expression (Choi et al., 1987).
PrP immunocytochemistry.
PrP staining was performed on live primary astrocytes using a 1:1000
dilution of humanized monoclonal anti-PrP antibody D13 (Williamson et al.,
1998). Following 1 hour incubation at room temperature, cells were fixed in 3.7%
formaldehyde in PBS for 20 minutes, washed in PBS, permeabilized in 0.1%
Triton x100, 0.1% sodium citrate for ten minutes, washed in PBS and labeled
with rabbit anti-GFAP (1:1500) (Dako, Carpinteria, CA) followed by Alexa
Fluor568 conjugated goat anti-rabbit IgG (1:3000) (Invitrogen, Carlsbad, CA) to
identify astrocytes and Alexa Fluor488 goat anti-human IgG (1:3000) (Invitrogen,
Carlsbad, CA) to visualize PrP staining. Fluorescent images were photographed
on an upright microscope (Olympus BX51) with a 10X objective using Microsuite
Analysis software. Control wells stained with secondary antibodies alone did not
show immunofluorescence.
Surface PrP staining and FACS analysis.
Purified WT and KO astrocytes were rinsed with PBS and removed from
T-25 flasks by incubation with 5mM EDTA for 15 minutes at 37°C. PrP staining
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was performed on 200,000 live primary astrocytes using 1 µg monoclonal
antibody D13, specific for PrP, in 50µL PBS. Following 1 hour incubation at 37°C,
cells were fixed in 3.7% formaldehyde in PBS for 20 minutes, blocked in 0.1M
glycine in PBS for 30 minutes and incubated for 1 hour at RT with 1 µg Alexa
Fluor488 goat anti-human IgG (Invitrogen, Carlsbad, CA) in 50µL PBS. Control
tubes of WT and KO astrocytes were fixed, blocked and incubated with Alexa
Fluor488 goat anti-human IgG alone. Data was collected by FACSCanto II flow
cytometer (Becton Dickinson, San Jose CA) and analyzed using FlowJo (Tree
Star, Ashland, OR).
Na+ dependent D-aspartate uptake assays.
Confluent astrocytes in 12 well plates were rinsed with a physiological
transport buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM KH2PO4,
0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 7.4) and
pre-incubated at 37 °C for 5 min. Transport rates were determined using 3H-Daspartate, which is effectively transported as an EAAT substrate, yet not
metabolized by cells following uptake (Koch et al., 1999). Transport assays were
carried out in which uptake was initiated by replacing the preincubation buffer
with buffer containing 3H-D-aspartate (5-300µM, 2-12µCi/ml). Following a fiveminute incubation, uptake was terminated by 3 consecutive washes with ice-cold
buffer. Cells were lysed with 0.4N NaOH for 24 hours and analyzed for
radioactivity by liquid scintillation counting and for protein by the bicinchoninic
acid method (Pierce, Rockford, IL). Uptake [pmol D-asp/min/mg protein] was
calculated and corrected for background radiolabel accumulation at 4°C.
Previous studies confirmed that uptake measured under these conditions was
linear with respect to time and protein content (Esslinger et al., 2005). Values are
reported as mean + SEM pmol/min/mg with each “n” value equaling the number
of determinations, each done in duplicate. Data was fit to the Michaelis-Menten
equation using non-linear regression (Prism 5). Transport of D-aspartate was
also measured in the presence of selective EAAT inhibitors: L-serine-O-sulfate
(LSOS) (Sigma Aldrich, St. Louis, MO), dihydrokainate (DHK) (Tocris Bioscience,
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Ellisville, MO), and TBOA (Tocris Bioscience, Ellisville, MO)), which were added
simultaneously at the indicated concentrations with 5µM 3H-D-aspartate.
Quantitative RT-PCR Analysis.
Purified astrocytes, 1 x 104, were seeded onto 24 well plates. Upon
reaching confluence, some wells were treated with 0.25mM dbcAMP for an
additional ten days. Confluent astrocytes were harvested with trypsin and lysed
using Qiashredder (Qiagen, Valencia, CA). Neuron – astrocyte cocultures as
described above were also harvested with trysin and lysed using Qiashredder
after 14 days in vitro. Total RNA was isolated using RNeasy mini kit with DNAse
treatment (Qiagen, Valencia, CA). RNA was reverse-transcribed into cDNA using
reverse transcription reagents with random hexamers (Applied Biosystems,
Foster City, CA). The cDNA product was then amplified in a new tube using gene
expression assays specific for the EAAT1 gene (Slc1a3), EAAT2 gene (Slc1a2),
and mouse β-actin gene (Applied Biosystems, Foster City, CA). Gene expression
was quantified using the first cycle number at which each sample reached a fixed
fluorescence threshold (CΤ). The quantity of expression of each gene was
normalized to mouse β-actin (∆ CΤ). Fold expression = 2 -∆ CΤ
Immunoblotting
Purified WT astrocyte cultures were washed briefly in 5ml cold PBS.
Astrocytes were lysed by shaking incubation with 1ml cold lysis buffer (5mM Tris
HCl p.H 7.4, 150mM NaCl, 5mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate,
1X Protease Inhibitor Cocktail) at 4°C for 5 minutes. Cell lysates were placed in a
pre-cooled 1.5ml centrifuge tube and centrifuged at 100g for 15 minutes.
Supernatants were collected and stored at -20°C. Protein concentration was
quantified using the bicinchoninic acid method (Pierce, Rockford,IL). cell lysates
(10ug) were boiled in 1X Sample Buffer containing Reducing Agent (Invitrogen,
Carlsbad, CA) for 3 minutes and loaded onto 4-12% Bis Tris gels (for EAAT1)
and 12% Tris-Glycine gels (for EAAT2). 4-12% Bis-Tris gels, used for assessing
monomeric and multimeric EAAT2 that runs at 64kDa and above, were run at
120 V for 4 hours in MOPS buffer. Proteins were electrophoretically transferred
onto a polyvinylidene fluoride membrane (37V, O/N). Membranes were blocked
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in TBS with 0.1% tween 20 containing 5% milk. Membranes were probed with
either antibodies specific for EAAT1 (1:2000, Tocris Cookson, St. Louis MO), or
actin (1:10,000, Sigma Aldrich, St. Louis, MO) in TBS–tween for one hour at
room temperature. Following three ten-minute washes with TBS-tween,
membranes were probed with appropriate horseradish peroxidase conjugated
secondary antibodies (EAAT 2 goat anti rabbit (1:3000); actin: goat anti-mouse
(1:3000)) diluted in TBS tween for one hour at room temperature. Visualization
was performed using chemiluminescence, according to manufacturer’s
recommendations (GE Healthcare Life Sciences, Pittsburg, PA).
L-Glutamate-mediated excitotoxicity.
At 14 days in vitro, neuron-glial co-cultures were exposed to varying
concentrations of L-glutamate (10-50µM) in 500µl fresh Neurobasal (Invitrogen,
Carlsbad, CA) media for ten minutes at room temperature. Following exposure,
cells were gently rinsed with HBSS, after which half their original media (250µl)
was added back to the well combined with 250µl fresh Neurobasal media with
B27 supplement to maintain original culture conditions. Twenty-four hours
following L-glutamate exposure, surviving neurons were enumerated. Cells were
fixed with 3.7% formaldehyde for 15 minutes, washed with PBS, permeabilized
with 0.1% Triton x100, 0.1% sodium citrate for ten minutes rinsed with PBS, and
labeled with mouse anti- MAP2 (1:1000) (Millipore, Billerica, MA) to identify
neurons followed by incubation with Alexa Fluor 488 conjugated goat anti- mouse
IgG (1:3000) (Invitrogen, Carlsbad, CA). Nuclei were visualized by incubation
with DAPI (Invitrogen, Carlsbad, CA). To count neurons, three randomly chosen
fields per well were photographed. The surviving MAP2-positive neuronal cell
bodies that colocalized with DAPI stained nuclei were quantified (Shin et al.,
2005). Neuronal survival following L-glutamate exposure was expressed as
percent survived relative to the total number of neurons counted in wells that had
not been exposed to L-glutamate. Data were obtained from 4 independent coculture experiments.
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Statistical Analysis
Statistical analysis was performed using non-parametric Mann-Whitney tests.
Calculations were performed on Prism GraphPad software (version 5). Statistical
significance was reported for values P<0.05.

Results
PrP expression on primary astrocytes
To confirm PrP expression on WT primary C57BL/10 astrocytes in vitro,
cortical astrocytes were purified from 1-2 day old mice and cultured in vitro for 7
days as described in Methods. Astrocytes from PrP KO mice were used as
negative controls. Cells were labeled with anti-GFAP, to identify astrocytes, and
with a monoclonal antibody, D13, reactive with PrP. As expected, the majority of
cells in both WT and PrP KO cultures were astrocytes and PrP immunoreactivity
was only observed on WT astrocytes and not on PrP KO astrocytes (Figure 21A). Primary WT and PrP KO astrocytes were also examined by flow cytometry
where live cells were labeled with D13. Surface expression of PrP was only
observed on WT astrocytes (Figure 2-1B).

Figure 2-1
Comparison of PrP expression on primary astrocytes harvested from WT and PrP KO mice
A. Live primary astrocytes from WT and PrP KO mice were labeled with anti-PrP monoclonal
antibody, D13 (green), fixed, permeabilized and labeled with anti-GFAP, specific for astrocytes
(red). Primary antibodies were visualized following incubation with Alexa Fluor-conjugated
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secondary antibodies as described in Methods. Nuclei were stained with DAPI. Results show
strong PrP staining on the cell surface of WT astrocytes and no PrP staining on PrPKO
astrocytes.
B. Study of surface PrP expression on WT and PrP KO primary astrocytes by flow cytometry. Live
astrocytes were labeled with primary antibody, D13 anti-PrP. D13 immunoreactivity was
measured by FACS following fixation and incubation with an Alexa Fluor-conjugated secondary
antibody as described in Methods. Graph shows cell frequency plotted versus fluorescence
intensity. WT astrocytes showed strong cell surface PrP staining and KO astrocytes showed no
detectable PrP staining.

Comparison of EAAT activity in WT and PrP KO astrocytes
We next examined the potential influence of PrP expression on Lglutamate homeostasis by analyzing EAAT–mediated transport by astrocytes
prepared from WT and PrP KO mice. Both EAAT1 and EAAT2 are localized to
astrocytes and are known to be responsible for the bulk of CNS glutamate
transport (Danbolt, 2001). Sodium-dependent transport assays were performed
using the non-metabolized EAAT substrate, D-aspartate, at a range of
concentrations. As shown in Figure 2-2A, transport rates between WT and PrP
KO astrocytes clearly diverged at concentrations of D-aspartate greater than
50µM. When fit to the Michaelis Menten equation, the Vmax values were 1.7 fold
higher in the PrP KO astrocytes compared to WT astrocytes (687 vs. 407
pmol/min/mg, Table 1-1 and Figure 2-2C).
Previous studies have demonstrated that treatment of primary astrocytes
with dibutyryl-cyclic AMP (dbcAMP) produces morphological and biochemical
changes more representative of astrocytes found in vivo (e.g. increased
expression of EAATs, GFAP, glutamine synthetase, and neurotransmitter
receptors) (Khelil et al., 1990; Le Prince et al., 1991; Miller et al., 1994; Jackson
et al., 1995; Hosli et al., 1997; Swanson et al., 1997; Schlag et al., 1998;
Daginakatte et al., 2008). Therefore, we also studied WT versus PrP KO
astrocytes treated for ten days with dbcAMP (0.25mM). Initial experiments also
confirmed that transport rates in the untreated cells were not significantly altered
by the additional ten days in culture (data not shown). When dbcAMP-treated
astrocytes were stained with D13 anti PrP, PrP immunoreactivity was only
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observed in WT astrocytes (data not shown). In transport experiments, PrP KO
astrocytes treated with dbcAMP exhibited a 2.5 fold increase in Vmax for Daspartate transport when compared to WT astrocytes treated with dbcAMP (1768
vs. 697 pmol/min/mg, Figure 2-2B, Figure 2-2D, and Table 2-1). This increase
was larger than the 1.7 fold increase observed in untreated astrocytes (Table 21). Thus, the highest Vmax for D-aspartate transport were found in cells lacking
PrP that had been treated with dbcAMP.
Though differences in Vmax were observed between WT and PrP KO
astrocytes both before and after treatment with dbcAMP, Km values were only
significantly different when astrocytes were cultured with dbcAMP (66 vs. 173µM,
Table 2-1). Alterations in Vmax values may reflect changes in either transporter
activity or expression. However, the observed change in Km between WT and
PrP KO astrocytes following dbcAMP treatment suggest that factors associated
with PrP may have a direct influence on transporter activity in the differentiated
cells.
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Figure 2-2
Comparison of D-aspartate transport by EAATs in WT and PrP KO astrocytes.
A. EAAT activity was measured in primary astrocytes derived from WT and PrP KO neonatal
mice cultured 7 days post-harvest. Astrocytes were incubated with 5µM, 10µM, 30µM, 75µM or
150µM D-aspartate, a non-metabolized analog of L-glutamate, for 5 minutes. Transport rate at
each concentration was measured (solid and open circles) and then fit to the Michaelis Menten
equation using non-linear regression (solid and dashed curves). Results are averages of data
from multiple independent observations (N=13 for WT, N=9 for PrP KO). Results show faster
transport by PrP KO astrocytes.
B. EAAT activity was measured in primary astrocytes, which were cultured in the presence of
dbcAMP for an additional 10 days. This treatment induced morphological and biochemical
changes in astrocytes including the increase in number of functional transporters. Astrocytes
were incubated with 5µM, 10µM, 30µM, 75µM, 150µM or 300µM D-aspartate for 5 minutes. As
expected, transport rates increased in both WT and PrP KO astrocytes (note the scale bar
difference between Figure 2-2A and 2-2B). Transport rate at each concentration of D-aspartate
(solid and open circles) was fit to the Michaelis Menten equation using non-linear regression
(solid and dashed curves). Data are averages of multiple independent observations (N=11 for
WT, N=9 for PrP KO). Results show faster transport by PrP KO astrocytes.
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C. The Vmax of EAAT-mediated transport for each experiment examining primary astrocytes 7
days post harvest is shown. WT astrocytes are respresented with solid circles and KO astrocytes
represented as solid squares. Results show higher Vmax values in PrP KO astrocytes.
D. Similar to 2-2C, the Vmax of EAAT-mediated transport for each experiment is shown examining
primary astrocytes treated with dbcAMP for ten additional days. Results show higher Vmax values
in dbcAMP-treated PrP KO astrocytes.

Table 2-1. Kinetics of D-aspartate transport in WT and PrP KO
astrocytes
Genotype Treatment

n

Km 1

Vmax2

WT

None

13

40 + 8

407 + 29

KO

None

9

63 + 19

687 + 614

WT

dbcAMP

11

66 + 10

KO

dbcAMP

9

173 + 29

697 + 57
6

1768 + 1005

Fold
Change3
1.7 + 0.19 x
2.5 + 0.2 x

Data from Figure 2-2 were fit by non-linear regression to the Michaelis
Menten equation. n is the number of independent observations. Vmax and Km
values are mean + SEM.
1

µM

2

pmol/min/mg protein

3

Fold increase in Vmax

4

p = 0.0007, comparison of Vmax in WT vs. PrP KO astrocytes. All statistics

were done using non-parametric Mann-Whitney u-test.
5

p = 0.0005, comparison of Vmax in dbcAMP-treated WT vs. PrP KO

astrocytes
6

p = 0.002, comparison of Km in dbcAMP-treated WT vs. PrP KO astrocytes.
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Evaluation of EAAT1 and EAAT2 expression and activity in WT and PrP KO
astrocytes
The increased Vmax values for transport observed in PrP KO astrocytes
could be due to alterations in transporter expression levels. Quantitative RT-PCR
was performed using mRNA from WT and PrP KO astrocytes. In untreated
astrocytes, EAAT1 expression was approximately 16-fold higher than EAAT2
expression (30% vs. 2% of actin expression, Figure 2-3A). As expected,
dbcAMP-treated astrocytes showed increased expression of both EAAT1 and
EAAT2 mRNA (Schlag et al., 1998). In dbcAMP treated astrocytes, EAAT1
expression was approximately 12.5-fold higher than EAAT2 (100% vs. 7% of
actin expression, Figure 2-3A). Therefore EAAT1 appeared to be the major
transporter observed in both untreated and dbcAMP-treated astrocytes. In
addition, EAAT1 mRNA levels were similar in PrP KO vs. WT astrocytes, and
likewise, EAAT2 mRNA levels were similar in these same cells (Figure 2-3A).
Therefore the increased transport observed in PrP KO astrocytes compared to
WT astrocytes did not correlate with increased production of either EAAT1 or
EAAT2 transporter mRNA.
Though dbcAMP treatment produces morphological and biochemical
changes more representative of astrocytes in vivo, including an increase of both
EAAT1 and EAAT2, co-culture with neurons can specifically induce EAAT2
expression (Gegelashvili et al., 1997; Swanson et al., 1997). Therefore, we also
evaluated EAAT subtype expression in WT and PrP KO astrocyte-neuron cocultures. Co-culture with neurons increased EAAT2 expression to 30% of actin
expression, which was also detectable at the protein level (Figure 2-3B).
However, EAAT1 expression was also increased in astrocyte-neuron co-cultures
to 100% of actin expression, though upregulation did not differ from what was
observed in dbcAMP astrocytes. Despite a 10-fold increase in EAAT2 expression
specific to co-culture with neurons, however, EAAT1 mRNA expression was still
higher than EAAT2 expression (100% vs. 30% of actin expression).
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A.

B.

Figure 2-3 EAAT expression in WT and PrP KO astrocytes
A. Analysis of EAAT1 and EAAT2 in WT and PrP KO astrocytes by real time RT-PCR.
EAAT1 and EAAT2 mRNA levels were quantified in WT and PrP KO (KO) astrocytes 7 days
following purification (as defined in Methods), following an additional 10 day treatment with
0.25mM dbcAMP (as described in Methods) or following 14 day co-culture with neurons of the
same genotype. Values shown are average ∆CT+ SEM of four - seven cultures where results
were normalized to mouse ß actin. A low ∆CT value corresponds to higher amount of transcript
detected. Though dbcAMP treatment and co-culture with neurons increased EAAT2 expression,
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EAAT1 expression was always higher in astrocyte cultures. In no comparison did PrP KO and WT
astrocytes differ from each other significantly in EAAT mRNA expression.
B. Immunoblot of EAAT2 in WT astrocytes. EAAT2 immunoblot of lysates prepared from
astrocytes 7 days following harvest (A) or following 14 day co-culture with WT neurons (A+N).
EAAT 2 expression, which is undetectable in primary astrocytes, is upregulated when astrocytes
are co-cultured with neurons.

To assess the contribution of individual EAAT subtypes to the total
observed transport of D-aspartate in WT and PrP KO astrocytes, transport of
5µM D-aspartate was measured in the presence of inhibitors that preferentially
act on individual EAAT subtypes (Bridges and Esslinger, 2005). In each of the
cultures, activity was markedly reduced in the presence of EAAT1 selective
inhibitor, LSOS (i.e. remaining activity was 20-30% of control measurements in
the presence of 500µM LSOS, Table 2-2). Consistent with these results, the
inclusion of the EAAT2 selective inhibitor, dihydrokainate (DHK,
300µM), produced much less inhibition and the remaining activity ranged from
73-89% of control (Table 2-2). Thus, the majority of uptake observed was
mediated by EAAT1 as predicted by our mRNA expression data (Figure 3A and
3B). This was similar to previous reports of primary in vitro astrocyte cultures,
including those treated with dbcAMP (Duan et al., 1999; Munir et al., 2000; Lin et
al., 2001; Adolph et al., 2007).
Because of the marked increase in EAAT2 mRNA expression observed in
astrocyte-neuron co-cultures, the pharmacological profile of WT and PrP KO cocultures was also assessed. In all co-cultures, D-aspartate activity was markedly
reduced in the presence of EAAT1 selective inhibitor, LSOS (i.e. remaining
activity was 20-32% of control measurements, Table 2-2), while activity in the
presence of EAAT2 selective inhibitor, DHK, produced much less inhibition (i.e.
remaining activity was 73-77% of control measurements, Table 2-2). Thus, while
EAAT2 mRNA and protein expression was increased in these co-cultures, its
contribution to L-glutamate transport was masked by the high amounts of EAAT1
expression.
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Table 2-2. D-aspartate transport in WT and PrP KO astrocytes in the
presence of various EAAT inhibitors

2

D-asp transport
(pmol/min/mg)

3

% activity retained in the presence of EAAT
1
Inhibitors
LSOS
DHK
TBOA
(EAAT1)
(EAAT2)
(EAAT 1-5)

Genotype

Treatment

WT

None

30 + 2

18 + 4 %

76 + 11 %

7+4%

PrP KO

None

31 + 3

20 + 4 %

89 + 8 %

8+4%

WT

dbcAMP

39 + 7

30 + 6 %

82 + 6 %

11 + 3 %

PrP KO

dbcAMP

38 + 2

26 + 3 %

73 + 13 %

9+3%

WT

Neurons

25 + 0

32 + 1 %

77 + 5 %

6+2%

PrP KO

Neurons

27 + 0

20 + 1 %

73 + 8 %

5+2%

1

Na+ dependent transport of 5µM D-aspartate was measured in the presence of

500µM LSOS, 300µM DHK or 500µM TBOA. These blockers were included in
the assays at concentrations estimated to block at least 80% of either EAAT1 or
EAAT2 activity. TBOA was used as a control for maximal inhibition with
specificity for both EAAT1 and EAAT2. Activity retained (% control) is shown as
mean + SEM of four independent observations.
2

WT and PrP KO were cultured for 7 days as described in Method, treated for an

additional ten days with 0.25mM dbcAMP to increase EAAT expression or were
cultured in the presence of neurons, as described in Methods for 14 days.
3

transport was measured at a concentration of 5µM D-aspartate.
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Comparison of sensitivity of WT and PrP KO neurons to glutamatemediated excitotoxicity
Numerous studies have concluded that inadequate clearance of Lglutamate by astrocytes can lead to excitotoxic neuronal death through excessive
activation of ionotropic excitatory amino acid receptors, especially the NMDA
subtype (Rosenberg and Aizenman, 1989; Choi, 1992; Speliotes et al., 1994).
Therefore, we tested the ability of WT and PrP KO astrocytes to protect neurons
of the same genotype from L-glutamate-mediated excitoxicity in vitro. After 14
days in culture, coinciding with NMDA receptor expression and the excitotoxic
vulnerability of neurons, the co-cultures of astrocytes and neurons were exposed
for ten minutes to L-glutamate at concentrations ranging from 10µM to 50µM.
The number of surviving neurons was quantified based on MAP2
immunoreactivity 24 hours later as previously described by Shin et al (Shin et al.,
2005). Compared to untreated controls, exposure to 20µM L-glutamate caused a
slight reduction in the number of both WT and PrP KO neurons (Figure 2-4A and
2-4B), although the morphology of WT and PrP KO neurons remained similar to
untreated controls (not shown). In contrast, exposure to 30µM and 40µM Lglutamate led to significantly reduced survival of neurons in the WT cultures
compared to neurons in the PrP KO cultures (Figure 2-5A). Furthermore, the
surviving neurons exhibited a decreased number of neurites and altered neurite
morphology (Figure 2-4C-F). At 50µM L-glutamate, both WT and PrP KO cultures
showed similar damage (Figure 2-4G and 2-4H). Thus, the increased EAAT
activity observed in the PrP KO cultures correlated with an increased resistance
to damage by a window (30µM and 40µM) of L-glutamate concentrations
compared to WT neurons cultured with WT astrocytes.
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Figure 2-4
Neuronal sensitivity to L-glutamate-mediated excitotoxicity.
Neuronal cultures derived from WT or PrP KO mice (gestational period 14-16) were plated onto a
bed of purified WT or PrP KO astrocytes, respectively, and co-cultured for 14 days as described
in Methods. On day 14, coinciding with NMDA receptor expression, co-cultures were exposed to
20µM (A-B), 30µM (C-D), 40µM (E-F) and 50µM (G-H) L-glutamate for 10 minutes. 24 hours
following exposure, co-cultures were fixed, permeabilized, and stained with anti-MAP2 to identify
neurons. MAP2 staining was visualized following incubation with an Alexa Fluor-conjugated
secondary antibody. Nuclei were visualized with DAPI. WT neurons showed more damage than
PrP KO neurons at glutamate concentrations of 30 and 40µM.
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Figure 2-5
Increased astrocytic protection against L-glutamate-mediated excitotoxicity by PrP KO
astrocytes.
A. Percent of MAP-2-positive WT or PrP KO neurons in neuron/astrocyte co-cultures 24 hours
following a ten minute L-glutamate exposure (30µM or 40µM). The data (mean + SEM) were
obtained from four independent co-culture experiments. Results show increased toxicity in
cultures with WT neurons co-cultured with WT astrocytes. Cultures of WT neurons and PrP
KO astrocytes showed significantly less toxicity. Experiments in which PrP KO neurons were
plated on WT astrocytes yielded variable results (data not shown), which are most likely the
result of contaminating PrP KO astrocytes from preparations of PrP KO neurons.
B. Percent of MAP-2 positive neurons in neuron/astrocytes co-cultures 24 hours following a ten
minute exposure to NMDA. The data (mean + SEM) were obtained from three independent
co-culture experiments as described in panel A. In the presence of NMDA, increased
neurotoxicity was seen in PrP KO co-cultures compared to WT co-cultures.

We next examined if PrP KO astrocyte cultures could similarly provide
increased protection to WT neurons. WT neurons were grown on a bed of
purified PrP KO astrocytes in the presence of 5µM cytosine arabinoside (as
described in Methods) to prevent WT astrocyte contamination and growth. After
exposure to 30µM and 40µM, WT neurons exhibited a higher degree of survival
when cultured on PrP KO astrocytes than when cultured on WT astrocytes
(Figure 2-5A). The levels of survival were similar to those observed when PrP KO
neurons were cultured with PrP KO astrocytes (Figure 2-5A). These data
demonstrated that PrP KO astrocytes were able to uniformly lessen the extent of
excitotoxic neuronal loss in both WT and PrP KO co-cultures.
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A previous report showed that PrP KO neurons were more vulnerable to
excitotoxicity than WT neurons when NMDA was used to induce the insult
(Khosravani et al. 2008). This was opposite to the results we observed using Lglutamate as the excitotoxic agonist. To study whether these differences might
be due to methodological differences or, more likely, to the inability of EAATs to
clear NMDA from the extracellular space, we tested the vulnerability of our
cultures to NMDA. When 1mM NMDA was added to our cultures in place of Lglutamate, KO neurons had a lower survival than did WT neurons (Figure 2-5B),
consistent with Khosravani et al. Taken together, these results suggest that
because L-glutamate is an EAAT substrate, the increased clearance by PrP KO
astrocytes functioned to counteract the oversensitivity of PrP KO neurons to
stimulation by excitatory receptor agonists.
Discussion
In our kinetic and pharmacological characterization of primary astrocyte
cultures, we observed increased EAAT activity in cells from PrP KO mice
compared to PrP expressing WT mice. This finding was observed in astrocytes
cultured both in the absence and presence of dbcAMP, which has been shown to
induce biochemical and morphological characteristics of astrocytes observed in
vivo (Khelil et al., 1990; Le Prince et al., 1991; Miller et al., 1994; Jackson et al.,
1995; Hosli et al., 1997; Swanson et al., 1997; Schlag et al., 1998; Daginakatte et
al., 2008). Furthermore, increased transport by PrP KO astrocytes was shown to
be functionally significant as KO astrocytes protected both KO and WT neurons
from L-glutamate-mediated excitotoxicity to a greater extent than did WT
astrocytes. Levels of L-glutamate are believed to reach millimolar levels in the
synaptic cleft during excitatory transmission (Clements et al., 1992) and are
rapidly cleared to markedly lower (0.1-1µM) homeostatic levels (Herman and
Jahr 2007). Therefore, the differences in Vmax observed between PrP KO and WT
astrocytes could have a marked influence on transmitter clearance and
glutamatergic signaling.
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Though the kinetic and physiological data clearly suggests that PrP KO
astrocytes have a greater capacity to transport L-glutamate, the underlying
mechanisms for increased EAAT activity have been difficult to ascertain. We
observed increased EAAT1 and EAAT2 activity in PrP KO versus WT astrocytes
without increased expression of either transporter. Given the very high levels of
EAAT protein present in these cultures, it has, however, been difficult to
accurately correlate expression with activity (Schlag et al., 1998). As an
alternative to higher total levels of EAAT protein, increased activity could be due
to indirect mechanisms that affect surface expression of the transporters and/or
changes in intrinsic activity, though we currently do not have data to differentiate
between these processes. As opposed to the changes in Vmax, the difference in
Km between dbcAMP-treated WT and PrP KO astrocytes argues for a direct
modulation of the transporters resulting in changed affinity for L-glutamate. LGlutamate transporters are subject to interactions with modulating proteins
(Jackson et al., 2001) and posttranslational modifications that can result in
altered transporter function (Adolph et al. 2007; Duan et al. 1999; Lin et al. 2001;
Munir et al. 2000, Schlag et al. 1998). PrP expression may be involved in such
modifications; we observed an increase in PrP mRNA expression following
dbcAMP treatment in WT astrocytes. The localization of PrP and EAATs to lipid
rafts may provide an environment conducive to interaction between these
molecules (Butchbach et al. 2004; Naslavsky et al. 1997). As functional data
indicate the majority of the transport quantified in the present experiments.
Including astrocyte-neuron co-cultures, is mediated by EAAT1, it suggests that it
is this subtype that is altered in the PrP KO astrocytes and leaves open the
issues as to whether or not PrP expression may also influence EAAT2 and
EAAT3.
In contrast to our findings, a previous study reported that cultures of
astrocytes expressing PrP transported L-glutamate at a faster rate than did PrP
KO astrocytes and that this difference was likely attributable to increases in Km
without a change in Vmax (Brown and Mohn 1999). However, the decease in the
rate of transport in the PrP KO astrocytes was only reported at a single
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concentration (100 µM). A number of methodological differences, including the
use of 3H-L- glutamate as a substrate rather than 3H-D-aspartate, determinations
of background and specific uptake, as well as treating the cells with dbcAMP,
make direct comparisons difficult. The most notable difference between the two
studies, however, concerns the genetics of the strains used to generate the cell
cultures. In the Brown and Mohn study, the PrP WT mice were (129/Sv(ev) x
C57BL/6J) F1 hybrids, while PrP KO mice were homozygous for a random
mixture of 129/Sv(ev) and C57BL/6J genes. Thus, the background genes of
these PrP KO mice differed completely from the WT mice used. In contrast, the
PrP KO mice used in our experiments were backcrossed nine times to
C57BL/10SnJ mice, which was used as the WT for comparison. Therefore, in
our PrP KO mice, only the Prnp (PrP) gene itself and areas immediately adjacent
to the Prnp gene were still of strain 129/Ola origin. It is possible that these
adjacent genes might also contribute to the differences observed in our
experiments.
Astrocytic EAATs mediate the fine balance between having sufficient Lglutamate in the synapse for neuronal signaling without exceeding the threshold
that would trigger excitotoxic pathology. To test if the increased transport
exhibited by PrP KO astrocytes was physiologically relevant, we studied the
toxicity of L-glutamate on mixed cortical cultures, where differences in transport
capacity have previously been shown to modulate susceptibility to excitotoxicity
(Rosenberg and Aizenman, 1989; Robinson et al., 1993; Rothstein et al., 1996).
In our experiments, PrP KO astrocytes treated with dbcAMP exhibited the
highest levels of transport (Table 2-1). Notably, co-culturing astrocytes with
neurons induces many of the same morphological and biochemical changes
induced by dbcAMP, including EAAT1 and EAAT2 expression (Gegelashvili et
al., 1997; Schlag et al., 1998; Perego et al., 2000). When co-cultures contained
PrP KO astrocytes, we found decreased evidence of excitotoxicity within a
narrow range of L-glutamate concentrations (Figure 2-5A), suggesting that
enhanced glutamate transport by PrP KO astrocytes, possibly at the rates seen
in dbcAMP-treated PrP KO astrocyte cultures, lessened neuronal death.
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However, this protection from L-glutamate-mediated excitotoxicity is
distinct from the increased neuronal vulnerability of PrP KO neurons to NMDAmediated excitotoxicity observed in our experiments (Figure 2-5B) and by others
(Khosravani et al 2008). Exposure to NMDA demonstrated that PrP KO neurons
are intrinsically more vulnerable than WT neurons to excitotoxic insults induced
by excessive NMDA receptor activation. While L-glutamate and NMDA are both
agonists at the NMDA receptor, L-glutamate transporters do not transport NMDA.
Thus, when NMDA was added to the mixed neuron-astrocyte co-cultures (Figure
2-5B), the experiment reflected the direct effect of NMDA on PrP KO and WT
neurons, as the EAATs could not transport NMDA and decrease its effective
concentration. In contrast, when L-glutamate was added (Figure 2-5A), astrocytic
transport of L-glutamate was able to alter its concentration, in agreement with the
D-aspartate uptake measurements, and reduce the excitotoxic challenge.
Unfortunately, the fragility of neurons precluded direct assays of transport
capacity in the co-cultures. Thus, increased transport of L-glutamate by PrP KO
astrocytes appeared to be effective in protecting PrP KO neurons from death
despite an increased vulnerability to excitotoxic injury. Similar results were
observed in the G93A SOD1 mouse model of amyotrophic lateral sclerosis where
a drug-induced increase in EAAT activity (approximately 2-fold) was shown to be
neuroprotective in vitro and delayed neuronal loss in vivo (Rothstein et al., 2005).
Increased clearance of L-glutamate by astrocytes in vivo may contribute to
the neurophysiological abnormalities observed previously in PrP KO mice. For
example, reduced excitatory post-synaptic potentials (Carleton et al. 2001),
impaired formation of long-term potentiation (Collinge et al. 1994; Criado et al.
2005; Manson et al. 1995), reductions in afterhyperpolarization potentials
(Mallucci et al., 2002) and abnormal responses to NMDA antagonist MK-801
(Coitinho et al., 2002) observed in PrP KO mice all suggest attenuation of Lglutamate-mediated signaling. Many of these alterations would be consistent with
the premature termination of the L-glutamate signal and/or the excessive
clearance of L-glutamate from the extracellular space surrounding EAA
receptors. Consistent with such a conclusion, the EAATs have been shown to
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regulate the extracellular levels of L-glutamate available to activate synaptic and
extrasynaptic receptors in specific excitatory circuits (Turecek and Trussell, 2000;
Dzubay and Otis, 2002; Huang et al., 2004; Diamond, 2005). Thus, the impact of
alterations in EAAT activity may be greatest in those synaptic connections
ensheathed by astrocytes, where the presence and positioning of the
transporters has been shown to modulate glutamatergic neurotransmission
(Anderson and Swanson, 2000; Bridges and Esslinger, 2005; Eulenburg and
Gomeza, 2010).
Low EAAT activity has been reported in a number of neurodegenerative
diseases, including amyotrophic lateral sclerosis (Rothstein et al., 1992), HIVassociated dementia (Sardar et al., 1999), and Alzheimer’s Disease (Masliah et
al., 1996). Increased levels of glutamate in the synaptic cleft may lead to
neuronal death through excitotoxicity (Beart and O'Shea, 2007). Accordingly,
enhancement of L-glutamate transport has been regarded as a potential
therapeutic goal. However, hyperactive EAAT activity and consequent reduced
NMDA receptor signaling is not without its own complications, as has been
suggested to be the case in schizophrenia (Miyamoto et al., 2005). Similarly, the
present work suggests that increased EAAT activity in the PrP KO mouse may
contribute to its neurophysiological phenotype. Taken together, therapeutic
approaches modulating EAAT activity in any disease will require targeting a level
of transporter activity that will maintain an optimal level of L-glutamate in the
synaptic cleft, balancing physiological and pathological signaling during all
phases of neuronal activity.
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ABSTRACT
Though the precise function of Prion protein (PrP) is unknown, numerous studies
suggest a role in glutamatergic neurotransmission. In chapter two, we showed that PrP
influenced L-glutamate signaling in vitro by impacting its clearance from the vicinity of
neurons. Therefore, we investigated whether similar localization of PrP and excitatory
amino acid transporters (EAATs) to lipid rafts influenced astrocytic EAAT activity.
Astrocytes were harvested from C57BL10 (WT) mice, PrP knockout (PrP KO) mice and
transgenic mice expressing a non-membrane, GPI anchorless form of PrP (tg88).
Though hypothesized that EAAT activity in PrP anchorless astrocytes would be the
same as PrP non-expressing astrocytes, tg88 EAAT activity did not mimic PrP KO
astrocytic EAAT activity. Further co-immunoprecipitation studies did not reveal a strong
interaction between WT PrP and EAAT1, the transporter subtype responsible for the
majority of transport activity in primary astrocytes. Thus, in these models, detectable
evidence for PrP and EAAT interaction within the lipid raft was not found.
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INTRODUTION
Increased EAAT activity in PrP KO astrocytes and the consequent ability to
reduce neuronal death following exposure to toxic levels of L-glutamate suggested that
expression of PrP regulated L-glutamate transport (Chapter 2). This modulation of
transport could be a result of upstream signaling events including RNA and protein
expression, unique to PrP expression. However, the association of PrP and the EAATs
to the plasma membrane may provide a location where these molecules can interact
PrP is a cell surface glycoprotein, bound to the outer leaflet of the plasma
membrane, attached by a GPI anchor (Stahl et al., 1987). GPI linked proteins are
typically localized to lipid rafts. In agreement, processed PrP is found in detergent
insoluble, cholesterol rich lipid raft microdomains (Naslavsky et al., 1997). However, the
physiological relevance of PrP localization to lipid rafts is unknown except in
susceptibility to TSE diseases (Speare et al., 2010). Attachment to the plasma
membrane is unique in amyloid diseases; TSEs are the only diseases in which the
converted protein is GPI anchored. However, transgenic mice that express PrP without
the GPI anchor (tg44) appear normal and are still susceptible to TSEs although they
present with markedly different clinical symptoms, pathology and incubation period
(Chesebro et al., 2005; Chesebro et al., 2010). Presumably, the physiological role of
PrP takes advantage of lipid raft locale as either an area in which PrP can modulate the
action of other proteins or, itself, be modulated.
The EAATs are trimeric, membrane-spanning proteins responsible for buffering
and transporting L- glutamate from the synaptic space. Astrocytic (EAAT1, EAAT2) and
neuronal (EAAT3, EAAT4) L-glutamate transporters are localized to cholesterol rich,
detergent insoluble, lipid rafts (Butchbach et al., 2004). Localization of neuronal Lglutamate transporters to lipid rafts influences the efficacy of L-glutamate transport
through the clustering of proteins that can modulate transport. Interaction of GTRAP3–
18 and EAAT3 has been shown to negatively modulate L-glutamate transport (Lin et al.,
2001). In contrast, GTRAP41 and GTRAP48 have been shown to increase EAAT4
mediated L-glutamate transport (Jackson et al., 2001). To date, lipid raft proteins which
interact with astrocytic EAATs have not been identified.
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In order to understand whether PrP negatively modulates astrocytic EAAT
activity, the interaction between PrP and EAATs were investigated. Coimmunoprecipitation experiments were performed investigating whether a strong
interaction between PrP and the EAATs existed. EAAT activity was also investigated
comparing astrocytes harvested from mice expressing GPI anchorless PrP (tg88),
membrane anchored, wild-type PrP (WT) or no PrP at all (PrP KO).
METHODS
Animals
C57BL/10SnJ (WT) mice were purchased from Jackson Labs (Bar Harbor, ME).
Homozygous PrP knockout (PrP KO) mice on the 129/Ola background (Manson et al.,
1994) were backcrossed nine times to C57BL/10SnJ mice selecting for the PrP KO
allele by PCR identification at each cross (Race et al., 2009). Transgenic GPI
anchorless PrP mice (tg44+/−) (Chesebro et al., 2005) were backcrossed to
C57BL/10SnJ-Prnp−/− mice for six to nine generations with selection for the Prnp−/−
genotype and the tg44+/− genotype. Heterozygous tg44+/- were then interbred to
create homozygous transgenic GPI anchorless PrP mice (tg44-/-, also known as tg88).
Thus these mice expressed anchorless PrP but lacked normal anchored mouse PrP
allele (Chesebro et al., 2010).
Astrocyte Cultures
Mixed glial cells were harvested from the cortices of WT and KO 1-2 day old
mice using modifications of the method of McCarthy and de Vellis (McCarthy and de
Vellis, 1980). Cortices, with meninges removed, were triturated, plated in T-25 flasks
with DMEM/F12 (Invitrogen, Carlsbad, CA) containing 15% fetal bovine serum
(HyClone, Omaha, NE) and maintained in a 5% CO2 incubator at 37°C. Approximately
seven days later, when cultures were confluent, microglia and oligodendrocytes were
removed from the astrocyte cultures by orbital shaking (overnight, 250 rpm). Purified
astrocyte cultures were harvested with trypsin. For D-aspartate uptake assays,
astrocytes were reseeded at 1 x 105 cells/well in 12 well plates and maintained with
fresh media every three days. In some experiments, astrocytes were assayed seven
days post-seeding, upon reaching confluence. In co-immunoprecipitation experiments,
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confluent cultures were treated with 0.25mM dibutyryl cyclic AMP (dbcAMP) (Sigma
Aldrich, St. Louis, MO) for an additional ten days with media changes including dbcAMP
every three days.
Na+ dependent D-aspartate uptake assays.
Confluent astrocytes in 12 well plates were rinsed with a physiological transport
buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM KH2PO4, 0.3 mM
Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 7.4) and pre-incubated at
37 °C for 5 min. Transport rates were determined using 3H-D-aspartate, which is
effectively transported as an EAAT substrate, yet not metabolized by cells following
uptake (Koch et al., 1999).Transport assays were carried out in which uptake was
initiated by replacing the preincubation buffer with buffer containing 3H-D-aspartate (5300µM, 2-12µCi/ml). Following a five-minute incubation, uptake was terminated by 3
consecutive washes with ice-cold buffer. Cells were lysed with 0.4N NaOH for 24 hours
and analyzed for radioactivity by liquid scintillation counting and for protein by the
bicinchoninic acid method (Pierce, Rockford, IL). Uptake [pmol D-asp/min/mg protein]
was calculated and corrected for background radiolabel accumulation at 4°C. Previous
studies confirmed that uptake measured under these conditions was linear with respect
to time and protein content (Esslinger et al., 2005). Values are reported as mean + SEM
pmol/min/mg with each “n” value equaling the number of determinations, each done in
duplicate. Data was fit to the Michaelis-Menten equation using non-linear regression
(Graph Pad Prism 5, GraphPad Software Inc, La Jolla, CA).
Co-immunoprecipitation
Purified WT astrocyte cultures were washed briefly in 5ml cold PBS. Astrocytes
were lysed by shaking incubation with 1ml cold lysis buffer (5mM Tris HCl p.H 7.4,
150mM NaCl, 5mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate, 1X Protease
Inhibitor Cocktail) at 4°C for 5 minutes. Lysates were placed in a pre-cooled 1.5ml
centrifuge tube and centrifuged at 100g for 15 minutes. Supernatants were collected
and stored at -20°C. Protein concentration was quantified using the bicinchoninic acid
method (Pierce, Rockford,IL).
Immunoprecipitation of PrP was done by incubating 0.1mg astrocyte lysate with
0.1M NaCl, antibodies specific for PrP: R30, R20, or R18 at indicated concentrations
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and co-IP buffer (50mM Tris HCl pH 7.5, 15mM EDTA, 100mM NaCl and 0.1% Triton X100 and 1X Halt Protease Inhibitor) to a final volume of 500µL. Antibody-lysate
complexes were incubated on ice for 90 minutes and occasionally inverted. A Protein Asepharose slurry was added to the tubes (50µL) and incubated with rotation for 45
minutes at 4°C. Immunoprecipitates were pelleted by centrifugation (1000rpm, 30
seconds) and washed 3 times with 1 ml co-IP buffer. Immunoprecipitates were collected
by boiling pellets for 5 minutes, centrifugation to pellet the beads, and collection of the
supernatant.
Immunoblot
One half of immunoprecipitate eluate or cell lysates (10ug) were boiled in 1X
Sample Buffer containing Reducing Agent (Invitrogen, Carlsbad, CA) for 3 minutes and
loaded onto 4-12% Bis Tris gels (for EAAT1) and 12% Tris-Glycine gels (for EAAT2). 412% Bis-Tris gels, used for assessing monomeric and multimeric EAAT1 that runs at
64kDa and above, were run at 120 V for 4 hours in MOPS buffer. 12% Tris Glycine gels
that were used to assess PrP expression, which runs at 33 KDa, were run for 1 hour at
120V. Proteins were electrophoretically transferred onto a polyvinylidene fluoride
membrane (37V, O/N). Membranes were blocked in TBS with 0.1% tween 20 containing
5% milk. Membranes were probed with either antibodies specific for EAAT1 (1:2000,
Tocris Cookson, St. Louis MO), PrP (1:5000, D13, Williamson et al. 1998) or actin
(1:10,000, Sigma Aldrich, St. Louis, MO) in TBS–tween for one hour at room
temperature. Following three ten-minute washes with TBS-tween, membranes were
probed with appropriate horseradish peroxidase conjugated secondary antibodies
(EAAT 1: goat anti rabbit (1:3000); PrP: rabbit anti human (1:3000); actin: goat antimouse (1:3000)) diluted in TBS tween for one hour at room temperature. Visualization
was performed using chemiluminescence, according to manufacturer’s
recommendations (GE Healthcare Life Sciences, Pittsburg, PA).
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RESULTS
Immunoprecipitation of PrP does not bring down EAAT1
Though PrP KO astrocytes exhibited higher EAAT activity compared to WT
astrocytes, detectable differences in mRNA expression were not observed, as
described in Chapter Two. In contrast to transport differences being mediated by
expression level, it is possible that PrP interacts with the EAATs, decreasing the rate
transport. Therefore, a direct interaction between PrP and EAAT1, the dominant
transporter operational in this primary culture system, was investigated.
PrP was immunoprecipitated from WT astrocyte cultures and protein-protein
interactions with EAAT1 were investigated. Low amounts of PrP were
immunoprecipitated when astrocytes were lysed in a non-ionic detergent buffer (Figure
1). Therefore, astrocytes were lysed in 0.5% sodium deoxycholate, 0.5% Triton X-100
and incubated alone or in combinations of three polyclonal rabbit antibodies specific for
PrP – R30 (89-103), R18 (142-155), and R20 (218-232). R30 alone was most efficient
at immunoprecipitating PrP (Figure 2). The addition of other antibodies in conjunction
with R30 did not increase the amount of protein immunoprecipitated. Monomeric
EAAT1, which in primary astrocyte cultures runs at approximately 65 kDa was not
observed in lysates that had been immunoprecipitated. EAAT 1 was also not coimmunoprecipitated in primary astrocytes treated with dbcAMP (Figure 3). The absence
of EAAT1 co-immunoprecipitates suggested that if any interaction between PrP and
EAAT1 existed, it was not preserved under these lysis conditions.
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Figure 3-1.
Assessment of ionic versus non-ionic detergent containing lysis buffers.
Two different lysis buffers were investigated to determine which was most effective at solubilizing PrP and
EAAT1. Astrocyte cultures lysed in a nonionic detergent consisting of 1% Triton-X100 was able to
solubilize EAAT1 to the same degree as the ionic detergents consisting of either 0.5% sodium
deoxycholate or 1% sodium deoxycholate, although interestingly, only multimeric forms of EAAT1 was
detected. In contrast, a marginal amount of PrP was solubilized with the non-ionic detergent compared to
the amount of PrP solubilized with 0.5% sodium deoxycholate. Therefore, in co-immunoprecipitation
experiments, 0.5% sodium deoxycholate was used as the astrocyte lysis buffer.
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Figure 3-2.
Co-immunoprecipitation of PrP and EAAT1 in primary WT and PrP KO astrocytes.
Astrocyte lysates were immunoprecipitated with 5ul and 2.5ul R30, R20 or R18. Lysates were also
immunoprecipitated with 2.5ul each of two of the above antibodies in combination to see if more PrP
could be latticed together and pulled down. 5ul and 2.5ul R30 pulled out the greatest amount of PrP from
WT astrocyte lysates compared to R20 and R18 alone. Compared to R30 alone, a detectable increase in
the amount of PrP pulled out with antibody combinations containing R30 was not observed. Interestingly,
the combination of R20 and R18 pulled out more PrP than either R20 or R18 alone. Therefore, R30 was
the best antibody to use for immunoprecipitating PrP. However, EAAT1 was not detected in any of the
immunoprecipitates. The band running approximately 50 KDa corresponds to IgG heavy chain.
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Figure 3-3.
Co-immunoprecipitation of PrP and EAAT1 in primary WT and PrP KO astrocytes treated with
dbcAMP.
Astrocyte lysates were immunoprecipitated with 2.5ul R30 and immunoblotted against PrP and EAAT1.
EAAT1 was not detected in immunoprecipitated lysates. The band running at approximately 50kDa
corresponds to IgG heavy chain.

Astrocytes expressing anchorless PrP do not differ in D-Aspartate transport
Lipid raft microdomains provide a membrane environment conducive to the
clustering and interaction of membrane bound proteins. Tg88 transgenic mice express
anchorless PrP that lacks the glycophosphatidylinositol anchor and thus is no longer
associated with the membrane and lipid raft, but is secreted (Chesebro et al., 2005).
Therefore, if similar location of PrP and the EAATs affected L-glutamate transport rates,
the absence of PrP from the membrane in Tg88 astrocytes should increase the EAAT
activity. Astrocytes from tg88 neonates were cultured and Na+ dependent transport of
D-aspartate was measured. At higher concentrations of substrate, tg88 astrocytes did
not significantly transport D-aspartate differently than WT or PrP KO astrocytes. The
Vmax of transport in tg88 astrocytes was also not significantly different from WT or PrP
KO astrocytes (tg88: 487+ 32, WT: 396+31, PrP KO: 657+44 pmol/min/mg). Though
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tg88 mice lacked PrP expression on the cell membrane, their transport of substrate did
not mimic transport observed in KO astrocytes.

Figure 3-4.
Comparison of D-aspartate transport by EAATs in WT, PrP KO and GPI-/- astrocytes.
A. EAAT activity was measured in primary astrocytes derived from WT and PrP KO neonatal mice
cultured 7 days post-harvest. Astrocytes were incubated with 5uM, 10uM, 30uM, 75uM or 150uM
D-aspartate, a non-metabolized analog of L-glutamate, for 5 minutes. Transport rate at each
concentration was measured and then fit to the Michaelis Menten equation using non-linear
regression. Results are averages of data from multiple independent observations. Results show
faster transport by PrP KO astrocytes.
B. The Vmax of EAAT-mediated transport for each experiment examining primary astrocytes 7 days
post harvest is shown. Results show intermediate Vmax values in GPI-/- astrocytes compared to
WT or PrP KO astrocytes (tg88: 487+ 32, WT: 396+31, PrP KO: 657+44 pmol/min/mg).

DISCUSSION
Because of the increased EAAT1 activity observed in PrP KO astrocytes, we
hypothesized that homeostatic levels of EAAT activity are governed by a direct
interaction between PrP and EAAT1. Both PrP and EAAT1 are membrane-associated
proteins localized to lipid rafts, a site where they could interact with each other either
directly or indirectly. For example, the unstructured N-terminal domain of PrP (residues
22-90) could transiently occlude the ability of glutamate to enter the bowl-shaped EAAT
and reduce its transport into the astrocyte.
However, co-immunoprecipitation experiments failed to reveal a strong proteinprotein interaction between PrP and EAAT1 although the experimental approach may
have prevented an ability to see such an interaction. The lysis conditions used to extract
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PrP contained an ionic detergent, which may have broken apart a protein-protein
interaction. It is possible that an interaction between PrP and EAAT1 was weak and
would not be maintained by the co-immunoprecipitation procedure, as might be
expected with a transient interaction. Because of previous data based on mRNA
expression and pharmacology of the PrP KO and WT astrocyte cultures, the majority of
transport was determined to be by the EAAT1 subtype (Chapter 2). Thus, coimmunoprecipitation experiments specifically looked for an interaction of PrP with
EAAT1 and not with EAAT2, which is expressed and functional albeit at markedly lower
levels compared with EAAT1. The possibility exists that modulation of glutamate
transport by PrP is subtype specific and that it acts on the less expressed EAAT2.
It is also possible that a direct interaction between PrP and the EAATs is not
what modulates transporter efficiency but location does. EAAT1, EAAT2 and PrP are all
localized to lipid rafts and such an environment may be conducive to the clustering and
interaction of proteins that serve to regulate levels of EAAT activity. If location was
indeed what mitigated transport,it was hypothesized that the lack of PrP membrane
anchoring in tg88 astrocytes would cause transport activity to mimic PrP KO astrocytes..
However, in tg88 astrocytes, moderate levels of transport were observed, not different
from WT or PrP KO astrocytes to which they were compared. However, expression
levels may explain why tg88 astrocytes demonstrate a phenotype similar to both PrP
KO and WT astrocytes. Tg88 astrocytes express a secreted PrP but at levels 4-5 times
less than WT PrP. If a direct interaction between PrP and EAAT1 did occur, possibly it
could happen between secreted PrP and EAAT1 and thus, the effect of PrP on EAAT
activity could be PrP dose dependent.
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ABSTRACT
Though highly expressed in the central nervous system, the function of prion
protein (PrP) is unknown. Abnormalities observed in PrP knockout (PrP KO) mice
suggest a function in L-glutamate mediated neurotransmission. Previously, we
showed that transport of D-aspartate, a non-metabolized L-glutamate analog,
through excitatory amino acid transporters (EAATs) was faster in astrocytes from
PrP knockout (PrP KO) mice than in astrocytes from C57BL/10SnJ wild-type
(WT) mice. However, since PrP KO mice contained 98.5% sequence identity to
the WT strain they were compared to, the difference in EAAT activity could be
attributed to the influence of allelic variants in other genes. Therefore, evaluation
of EAAT activity in astrocytes harvested from transgenic PrP expressing mice
with mixed genetic backgrounds was performed. Astrocytes harvested from a
PrP over-expressing mice (tga20 +/-) did not transport D-aspartate faster than
PrP null littermates (tga20 -/-). Astrocytes harvested from mice expressing
hamster PrP only on neurons (tgNSE) did not transport D-aspartate faster than
hamster PrP over- expressing astrocytes (tg7). Experiments altering PrP
expression using PrP silencing in WT astrocytes and PrP transduction in PrP KO
astrocytes had varied results due to variable expression changes. Taken
together, these studies suggest WT expression levels of PrP may regulate EAAT
activity.
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INTRODUCTION
Though evolutionarily conserved, developmentally regulated, and highly
expressed in numerous tissues, the physiological function of prion protein (PrP)
is unknown. Mice devoid of PrP expression (PrP KO) develop normally and do
not exhibit gross abnormalities (Bueler et al., 1992; Manson et al., 1994).
However, PrP KO mice exhibit several subtle abnormalities suggesting that PrP
plays a role in cellular homeostasis (reviewed in Chapter one), including
maintenance of L-glutamate concentrations in the synaptic cleft through
regulating the activity of excitatory amino acid transporters (EAATs) (Chapter
Two).
PrP KO mice were originally generated through disruption of the Prnp
gene on chromosome 2 by homologous recombination of embryonic stem (ES)
cells (Bueler et al., 1992; Manson et al., 1994). In the Edinburgh line of PrP KO
mice, ES cells from 129/Ola mice were electroporated with recombinant DNA
containing a neo insertion in the Prnp gene (Manson et al., 1994). Following
selection, resulting mice were PrP null on a 129/Ola background. Functions of
PrP could be assessed comparing these mice to 129/Ola wild type mice and
such studies demonstrated that PrP KO mice had decreased LTP (Manson et al.,
1995) and mitochondrial abnormalities (Miele et al., 2002).
However, maintenance of the PrP KO line on a 129/Ola background has
been notoriously difficult and in many laboratories, mice were crossed to better
breeding lines of mice such as C57BL/10. Despite multiple backcrosses, genetic
purity of the C57BL/10 strain cannot be re-established and genes immediately
flanking the Prnp gene locus will be of 129/Ola origin. The PrP KO mice used to
assess the influence of PrP on EAAT activity were on the C57BL/10 background
though areas immediately surrounding the Prnp gene locus may have 129/Ola
genetic determinants (Figure 4-1). Thus, allelic variation in other genes may have
accounted for the differences observed.
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Figure 4-1. Schematic of the Prnp gene on chromosome 2 and the area immediately
surrounding the Prnp gene in wildtype and PrP KO mice.

In an effort to distinguish whether abnormal levels of EAAT activity
observed in PrP KO astrocytes was due to the lack of PrP expression or flanking
genes from the 129/Ola strain, activity was measured in PrP expressing and nonPrP expressing astrocytes. In some experiments, astrocytes were harvested from
transgenic lines of mice who contain a neo cassette in the Prnp gene but whose
PrP expression is driven on another chromosome. In other experiments, PrP
expression was either silenced or induced.
MATERIALS AND METHODS
Animals
C57BL/10SnJ (WT) mice were purchased from Jackson Labs (Bar Harbor,
ME). Homozygous PrP knockout (PrP KO) mice on the 129/Ola background
(Manson et al., 1994) were backcrossed nine times to C57BL/10SnJ mice
selecting for the PrP KO allele by PCR identification at each cross (Race et al.,
2009). Homozygous tgNSE (Race et al., 1995), tgGFAP (Raeber et al., 1997)
and tg7 (Race et al., 1995) mice, originally on a mixed background were
subsequently backcrossed to PrP KO mice to eliminate mouse PrP gene
expression, as described (Race et al., 2000). Tga 20 mice (Fischer et al., 1996),
on a mixed background, were in the process of being backcrossed to PrP KO
mice. Tga20 mice were bred with PrP KO mice and resulting offspring were
distinguished by PCR as either heterozygous for the tga20 transgene (+/-) or
homozygous null mice for the tga 20 transgene (-/-). This generation of
experimental mice was approximately 93% C57BL/10.
Astrocyte Cultures
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Mixed glial cells were harvested from the cortices of WT and KO 1-2 day
old mice using modifications of the method of McCarthy and de Vellis (McCarthy
and de Vellis, 1980). Cortices, with meninges removed, were triturated, plated in
T-25 flasks with DMEM/F12 (Invitrogen, Carlsbad, CA) containing 15% fetal
bovine serum (HyClone, Omaha, NE) and maintained in a 5% CO2 incubator at
37°C. Approximately seven days later, when cultures were confluent, microglia
and oligodendrocytes were removed from the astrocyte cultures by orbital
shaking (overnight, 250 rpm). Purified astrocyte cultures were harvested with
trypsin. For D-aspartate uptake assays, astrocytes were reseeded at 1 x 105
cells/well in 12 well plates and maintained with fresh media every three days. In
some experiments, astrocytes were assayed seven days post-seeding, upon
reaching confluence.
Na+ dependent D-aspartate uptake assays.
Confluent astrocytes in 12 well plates were rinsed with a physiological
transport buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM KH2PO4,
0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 7.4) and
pre-incubated at 37 °C for 5 min. Transport rates were determined using 3H-Daspartate, which is effectively transported as an EAAT substrate, yet not
metabolized by cells following uptake (Koch et al., 1999). Transport assays were
carried out in which uptake was initiated by replacing the preincubation buffer
with buffer containing 3H-D-aspartate (150µM, 10µCi/ml). Following a five-minute
incubation, uptake was terminated by 3 consecutive washes with ice-cold buffer.
Cells were lysed with 0.4N NaOH for 24 hours and analyzed for radioactivity by
liquid scintillation counting and for protein by the bicinchoninic acid method
(Pierce, Rockford, IL). Uptake [pmol D-asp/min/mg protein] was calculated and
corrected for background radiolabel accumulation at 4°C. Previous studies
confirmed that uptake measured under these conditions was linear with respect
to time and protein content (Esslinger et al., 2005). Values are reported as mean
+ SEM pmol/min/mg with each “n” value equaling the number of determinations,
each done in duplicate. Data was fit to the Michaelis-Menten equation using nonlinear regression (Graph Pad Prism 5, GraphPad Software Inc, La Jolla, CA).
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Immunoblot
Purified astrocyte cultures were washed briefly in 5ml cold PBS.
Astrocytes were lysed by shaking incubation with 1ml cold lysis buffer (5mM Tris
HCl p.H 7.4, 150mM NaCl, 5mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate,
1X Protease Inhibitor Cocktail) at 4°C for 5 minutes. Lysates were placed in precooled 1.5ml centrifuge tubes and centrifuged at 100g for 15 minutes.
Supernatants were collected and stored at -20°C. Protein concentration was
quantified using the bicinchoninic acid method (Pierce, Rockford, IL). Cell lysates
were boiled in 1X Sample Buffer containing Reducing Agent (Invitrogen,
Carlsbad, CA) for 3 minutes and loaded 16% Tris Glycine gels that were used to
assess PrP expression, which runs at approximately 33-37 KDa . Gels were run
for 1 hour at 120V. Proteins were electrophoretically transferred onto a
polyvinylidene fluoride membrane (37V, O/N). Membranes were blocked in TBS
with 0.1% tween 20 containing 5% milk. Membranes were probed with antibody
specific for PrP (D13, 1:5000 (Williamson et al., 1998)) in TBS –tween for one
hour at room temperature. Following three ten-minute washes with TBS-tween,
membranes were probed with rabbit anti human (1:3000) diluted in TBS tween
for one hour at room temperature. Visualization was performed using
chemiluminescence, according to manufacturer’s recommendations (GE
Healthcare Life Sciences, Pittsburg, PA).
Transfection of primary astrocytes with siRNA
Purified WT and PrP KO astrocytes were plated in 12 well plates at a
density of 75,000 cells/well. Approximately four days later, when cell appeared
75% confluent, astrocytes were transfected with 2.5nM, 5nM, 10nM siRNA
against Prnp (siRNA ID # s72188, Applied Biosystems, Carlsbad, CA ) or 30nM
scrambled siRNA or 30nM GAPDH siRNA both of which came with the
transfection reagent and were used at concentrations recommended by the
manufacturer. siPORT Amine transfection reagent (Applied Biosystems,
Carlsbad, CA) was used at 1.5ul per well which was previously determined to be
a reagent and concentration sufficient to silence GAPDH expression without
causing visible toxicity to astrocytes. siPORT Amine was diluted in 23.5ul
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OPTIMEM (Invitrogen, Carlsbad, CA) and incubated for ten minutes at room
temperature. Meanwhile, siRNA at the indicated concentrations above was
diluted in OPTIMEM to a final volume of 25ul. Both diluted siRNA and diluted
transfection reagent were mixed and incubated together at room temperature for
an additional ten minutes. Complexes were placed onto cells and incubated for
72 hours in a 37°C, 5% CO2 incubator for 72 hours at which point cells were
stained harvested for FACS analysis or assayed for Na+ dependent D-aspartate
transport assays. For immunofluorescent staining, astrocytes were plated onto
chamber slides and transfection was scaled down to 0.3ul siPORT amine
transfection reagent in 10ul OPTIMEM and 10ul diluted siRNA.
Viral transduction of primary astrocytes
PrP KO astrocytes were transduced with supernatant from Psi2 cells who
had been tranfected with retrovirus pSFF or pSFF in which hamster PrP had
been cloned (graciously given by Suzette Priola, Rocky Mountain Labs, Hamilton
MT). Astrocytes were transduced with 500ul stock virus in the presence of
4ug/ml polybrene. In some wells, astrocytes were treated with 4ug polybrene
alone. Astrocytes were incubated at 37°C at 5% CO2. Media was completely
replaced 24 hours after transduction and assessment of PrP expression by
FACS analysis and D-aspartate transport assays performed 7 days after
transduction.
Surface PrP staining and FACS analysis
Astrocytes plated in chamber slides were rinsed with PBS 3 times and
stained live for PrP using 1ug monoclonal antibody D13, specific for PrP diluted
in PBS with 2% FBS. Following 30 minute incubation at 37°C and 3 washes with
PBS, astrocytes were fixed in 3.7% formaldehyde for 20 minutes at room
temperature, washed and permbealized in 0.1% tx-100 and 0.1% sodium citrate
for 10 minutes at room temperature. Cells were then blocked in 0.1M glycine for
30 minutes and with NGS/BSA for an additional 30 minutes. Cells were labeled
with anti-GFAP (1:1500) (Dako, Carpinteria, CA) conjugated with AlexaFluor568
goat anti-rabbit IgG (1:3000) (Invitrogen, Carlsbad, CA) to identify astrocytes and
AlexaFluor488 goat anti-human IgG (1:3000) (Invitrogen, Carlsbad, CA) to
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visualize PrP staining. Fluorescent images were photographed on an upright
microscope (Olympus BX51) with a 10X objective using Microsuite Analysis
software. Control wells stained with secondary antibodies alone did not show
immunofluorescence.
For FACS analysis, astrocytes were rinsed with PBS and removed from T25 flasks by incubation with 0.5mM EDTA for 15 minutes at 37°C. PrP staining
was performed on 200,000 live primary astrocytes using 1 µg monoclonal
antibody D13, specific for PrP. Following 1 hour incubation at 37°C, cells were
fixed in 3.7% formaldehyde for 20 minutes, blocked in 0.1M glycine for 30
minutes and incubated for 1 hour at 22°C with 1 µg AlexaFluor488 goat antihuman IgG (Invitrogen, Carlsbad, CA). Sister tubes of WT and KO astrocytes
were fixed, blocked and incubated with AlexaFluor488 goat anti-human IgG
alone. Data was collected by FACSCanto II flow cytometer (Becton Dickinson,
San Jose CA) and analyzed using FlowJo (Tree Star, Ashland, OR).
RESULTS
PrP KO mice contain non-C57BL10 allelic variants
Though the PrP KO mice used in the experiments described in chapters
two and three had been serially backcrossed nine times to homozygous
C57BL10 mice, it was possible that genes immediately adjacent to the Prnp gene
locus could still be of 129/Ola origin. These genes, which may have differed from
the WT mice used in experiments, could have also played a role in the increased
transport observed in PrP KO mice. Therefore, DNA from C57BL10 and PrP KO
mice were compared using SNP analysis. Non-C57BL10 SNPs were found in
submitted PrP KO mice only on chromosome two in a 48 mega base pair region
surrounding the Prnp gene locus. This region of differences contains 556 genes,
including Slc1a2 which encodes EAAT2.
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EAAT activity in astrocytes harvested from transgenic mice expressing hamster
PrP
Since genes other than PrP may have contributed to the differences in
EAAT activity observed between astrocytes harvested from congenic PrP KO
and WT mice, rescue experiments were performed using mice containing a PrP
transgene. These transgenic mice were backcrossed to PrP KO mice several
times. Importantly, these mice contained the neo insertion in the Prnp gene on
chromosome 2 and contained the same flanking genes surrounding the Prnp
gene locus (Figure 4-2).

Figure 4-2. Comparison of astrocytes harvested from mice containing a PrP transgene.
Transgenic PrP expressing mice contain a neo insertion in the Prnp gene on chromosome 2 as
well as genes linked to the Prnp gene locus (red). Transgene insertion on chromosome n leads to
cell-specific PrP expression, ie astrocyte specific or neuron specific (yellow). Trangenic mice
contain 129/Ola genes (blue) but contain 93-98% genetic identity to the C57BL/10 strain. All
astrocytes compared for EAAT activity contain the PrP KO gene complex.

PrP expression was confirmed on astrocytes harvested from hamster PrP
expressing transgenic lines of mice. Tg-NSE mice express hamster PrP driven
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by neuron specific promoter, NSE. Tg-7 mice overexpress hamster PrP on
multiple cell types. As expected, FACS analysis of surface PrP expression
demonstrated that tg7 and C57BL10 WT astrocytes express PrP whereas TgNSE astrocytes did not express any PrP (Figure 4-3A). Furthermore, levels of
PrP expression were higher in tg7 astrocytes, consistent with overexpression in
total brain. Immunoblot of whole astrocyte lysate also revealed overexpression of
PrP in tg7 astrocytes compared to C57BL/10 WT astrocytes (Figure 4-3B).

Figure 4-3. PrP expression on primary astrocytes harvested from PrPexpressing transgenic mice.
A. FACS detection of surface PrP expression on astrocytes harvested from C57BL/10, tgNSE
and tg7 mice. Live primary astrocytes were labeled with D13, specific for PrP. Only C57BL/10
astrocytes and tg7 astrocytes express PrP. TgNSE astrocytes show the same fluorescent
intensity as astrocytes labeled with secondary antibody alone. B. PrP immunoblot of lysates
prepared from WT, tga20 and tg7 purified astrocyte cultures.

The influence of PrP expression on EAAT mediated glutamate transport
was investigated by measuring EAAT activity in astrocytes harvested from PrP
expressing transgenic mice. In these experiments, tgNSE astrocytes, tg7
astrocytes and tgGFAP astrocytes were compared. Tg-GFAP mice express
hamster PrP driven by the GFAP promoter, and thus, only express PrP on glial
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cells (Raeber et al., 1997) though with expression in total brain much lower
compared to WT brains. Sodium dependent transport assays were performed
using the non-metabolized EAAT substrate, D-aspartate, at 150uM, a
concentration high enough to delineate activity differences (Chapter 2). As shown
in Figure 4-4, transport of 150uM D-aspartate was indistinguishable between
tgNSE astrocytes, tgGFAP astrocytes and tg7 astrocytes (459+26, 372+46,
451+32 pmol/min/mg respectively, Figure 4-4). Astrocytes were treated with
0.25mM dbcAMP for ten days to increase EAAT1 and EAAT2 expression and
thereby increase transport velocities that might distinguish the different
transgenic lines of astrocytes (Chapter 2). However, treatment of dbcAMP
treatment, while increasing transport, also did not reveal differences between
tgNSE, tgGFAP or tg7 astrocytes (597+42, 658+34, 588+94 pmol/min/mg
respectively, Figure 4-4). Thus, in both untreated and dbcAMP treated
astrocytes, lack of hamster PrP expression did not change EAAT activity
compared to low expression of PrP or overexpression of PrP.
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Figure 4-4. EAAT activity in tgNSE, tgGFAP and tg7 astrocyes. Uptake of 150uM D-aspartate
was quantified in primary astrocytes cultured from tgNSE, tgGFAP and tg7 mice, which differ in
levels of hamster PrP expression.

EAAT activity in astrocytes harvested from transgenic mice expressing mouse
PrP
Similar experiments attempting to rescue the difference observed between
PrP KO and WT mice were performed on a line of transgenic mice, tga20, who
overexpress mouse PrP (Fischer et al., 1996) and were in the process of being
backcrossed to PrP KO mice. Littermates were either heterozygous at the tga20
locus and expressed 3-fold higher levels of PrP (tga20 +/-), or were null at the tga
20 locus and did not express PrP (tga20 -/-). Littermates all contained the Prnp
null gene complex on chromosome 2 (Figure 4-2). Immunoblot lysates of primary
astrocytes harvested from tga20 mice demonstrated overexpression of PrP
compared to WT astrocytes (Figure 4-3B). When transport of 150uM D-aspartate
was measured in tga20 astrocytes, a difference between tga20 +/- PrP
expressing and tga20 -/- PrP non-expressing astrocytes was not observed
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(455+40 vs. 483+22 pmol/min/mg respectively, Figure 4-5). A difference in
transport velocity was also not observed in dbcAMP treated tga20 +/- vs tga20 -/astrocytes (947+68 vs. 741+62 pmol/min/mg, respectively, Figure 4-5). Thus,
overexpression of mouse PrP compared to non-expression also did not rescue
the EAAT activity differences observed between WT and PrP KO astrocytes.

Figure 4-5. EAAT activity in tga20 +- and tga20 -/- astrocytes. Uptake of 150uM D-aspartate
was quantified in primary astrocytes cultured from tga20 +/- and tga20 -/ astrocytes which
overexpress or do not express mouse PrP.

EAAT activity in KO astrocytes transduced to express PrP or WT astrocytes with
silenced PrP expression
Usage of transgenic mice to describe EAAT activity as a function of PrP
expression is still prone to the influence of background genes. Therefore, EAAT
mediated D-aspartate transport was measured in WT astrocytes whose PrP
expression was silenced and PrP KO astrocytes induced to express PrP.
To rescue the PrP KO phenotype, PrP expression was silenced in WT
astrocytes by transfecting Prnp specific siRNA, as described in Methods. Levels
of PrP silencing between experiments were variable and may have depended on
how the detection method of PrP expression. In some experiments when
immunoblot and immunostaining of PrP KO astrocytes were employed, silencing
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specific to siRNA against Prnp compared to a scambled siRNA sequence was
observed (data not shown). However, FACS analysis showed surface reduction
of PrP expression independent of the siRNA sequence (Figure 4-6A.). When the
effect of silencing PrP on EAAT activity was assayed, an increased in Daspartate transport was observed in all conditions and was probably the result of
siRNA transfection (Figure 4-6B).

Figure 4-6. Knockdown of PrP expression following transfection with Prnp specific siRNA.
A. FACS detection of surface PrP expression on C57BL10 WT astrocytes 72 hours following
transfection with siRNA against PrP or a scrambled siRNA sequence. Live primary astrocytes
were labeled with D13, specific for PrP. expression. In this experiment, a reduction in PrP
expression is observed independent of siRNA sequence. B. Uptake of 150uM D-aspartate was
quantified in primary PrP KO and WT astrocytes following 72 hours transfection with either siRNA
against PrP or a scrambled sequence. In all treatments, there was an increase in EAAT activity.

To rescue PrP expression in PrP KO astrocytes in an attempt to mimic the
WT phenotype, PrP expression was induced in PrP KO astrocytes and EAAT
activity was measured. PrP KO astrocytes were transduced in the presence of
polybrene with retrovirus pSFF in which hamster PrP had been cloned. While
levels of expression varied experiment to experiment (ranging from 45% - 60%,
Figure 4-7A), PrP KO astrocytes did express PrP. However, PrP KO astrocytes
expressing PrP did not exhibit reduced transport compared to PrP KO astrocytes
not expressing PrP (Figure 4-7B).
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Figure 4-7. EAAT activity following induction of PrP expression in PrP KO astrocytes. A.
FACS detection of surface PrP expression 7 days following transduction with pSFF-haPrP in the
presence of 4ug/ml polybrene (pb). Live primary astrocytes were labeled with D13, specific for
PrP. expression. Compared to PrP KO astrocytes, 50% transduced astrocytes expressed PrP. B.
Uptake of 150uM D-aspartate was quantified in PrP KO and WT astrocytes seven days following
transduction. PrP KO astrocytes transduced to express PrP did not have decreased transport
compared to untreated KO astrocytes.

DISCUSSION
The experiments described in this chapter were aimed at replicating the
observation that PrP KO astrocytes have higher EAAT activity than WT
astrocytes. The phenotype observed could not be definitively attributed to PrP
expression; the mice compared were genetically identical except at chromosome
2 in the region surrounding the Prnp gene. Here, 129/Ola genes existed in PrP
KO astrocytes, different than the C57BL10 astrocytes, and thus differences
observed could be due to the expression of these 129/Ola genes. The gene
encoding EAAT2, Slc1a2, is located in this region and according to SNP
analysis, differs between WT and PrP KO mice. Of note, most of the transport in
the system studied was due to EAAT1 encoded by Slc1a3, located on a
chromosome 11 and lacking any genetic differences between PrP KO and WT
mice.
These experiments used astrocytes harvested from transgenic mice
whose PrP expression driven by a promoter other than the PrP promoter and
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whose genome contained the Prnp KO gene complex. If 129/Ola genes flanking
the Prnp KO gene locus contributed to the differences observed in PrP KO
versus WT astrocytes, these transgenic mice would have the same 129/Ola
genes and EAAT would be similar. In experiments examining EAAT activity in
PrP-expressing transgenic mice, PrP expression did not rescue the WT
phenotype. The simplest explanation therefore is expression of129/Ola genes in
the area surrounding the Prnp KO gene locus did play a role in the EAAT activity
differences observed between WT and PrP KO astrocytes.
However, there are important caveats to interpreting EAAT activity in PrP
expressing transgenic mice. The tga20 mice used in this study are of a mixed
background. Other genes on other chromosomes may be different between the
lines of mice compared, i.e. Slc1a3 encoding for EAAT1. Furthermore, the PrP
expressing transgenic mice did not express wild-type levels of PrP. Interestingly,
the two comparisons that showed similar levels of transport, tgNSE vs tg7 and
tga20+/- vs. tga20-/-, both compared the lack of PrP expression to the
overexpression of PrP. Transgene expression can lead to phenotypes by itself
either due to site of insertion, abnormal expression or overexpression. Tga20
mice have disturbed T cell development (Jouvin-Marche et al., 2006; Zabel et al.,
2009), increased susceptibility to kainic acid induced seizures and decreased
synaptic facilitiation and long term potentiation (Rangel et al., 2009). Aggregation
of PrP has been described in other PrP overexpressing transgenic mice
(Westaway et al., 1994; Chiesa et al., 2008). The inability, therefore, of the
rescue experiments to mimic EAAT activity observed in PrP KO and WT mice
may be due to other reasons unrelated to the Prnp gene and genes flanking the
region on chromosome two.
Multiple approaches to understanding the influence of PrP on EAAT
activity were taken. This includes assessment of another PrP knockout line,
Zurich PrP 0/0 and the strain used to make the knockout mouse, 129/Ola (data
not shown). However, because of the same caveats described, interpretation is
limited. With siRNA and viral transduction experiments, the efficiency of
manipulation was variable and made comparisons against untreated astrocytes
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difficult. The best comparison performed was that comparing C57BL/10 wildtype
and PrP KO mice who share 98.6% genetic identity. The only comparison better
would be studying the PrP knockout on the 129/Ola background, which will be
accomplished in future studies.
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CHAPTER FIVE
CONCLUSION
Two questions hover over the fields of prion protein (PrP) biology and excitatory
amino acid transporter (EAAT) biology: what is the function of PrP and how is EAAT
activity controlled. Multiple lines of evidence demonstrate that both PrP and the EAATs
regulate aspects of L-glutamate neurotransmission though a link between them has not
been demonstrated. The overall aim of this dissertation research was to use PrP KO
mice as a tool to characterize the influence of PrP on astrocytic EAAT mediated Lglutamate transport. We found that astrocytes harvested from PrP KO mice displayed
abnormal EAAT activity that was mediated primarily by the EAAT1 subtype. However,
the similar localization of the EAATs and PrP to lipid rafts did not appear to control
EAAT activity nor did overexpression of PrP. Thus, WT PrP expression appeared to
regulate astrocytic EAAT activity.
How might PrP be regulating EAAT activity? EAAT activity is regulated at
multiple levels: DNA transcription, translation, post-translational modifications and
localization. At the level of detection, PrP expression did not influence transcriptional
regulation of EAAT1 or EAAT2 (Chapter 2). PrP expression may influence posttranslational modifications of the EAATs that may subsequently affect functional
properties of the EAATs. For example, EAAT 1 is glycosylated in the extracellular loop
of transmembrane helices 3 and 4 (Conradt et al., 1995) and it was not addressed in
this research whether PrP expression alters the ratio of unglycosylated versus
glycosylated forms. However, the role of EAAT glycosylations is unknown as both forms
traffic to the plasma membrane and show similar levels of uptake activity (Conradt et al.,
1995; Raunser et al., 2005). Therefore, the likelihood that PrP affects glycosylation of
the EAATs is possible though mediating functional outcomes is unlikely.
If not through transcriptional regulation or post-translational modification, PrP
may influence EAAT activity by location. Both PrP and EAATs are localized to lipid rafts
(Stahl et al., 1987; Butchbach et al., 2004) and such a locale may be conducive to a
direct or indirect interaction between them. In Chapter 3, we investigated the importance
of PrP lipid raft localization to EAAT mediated transport by utilizing PrP mutant mice
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(tg88) which express a soluble form of PrP. Uptake measurements in tg88 astrocytes
did not demonstrate transport activity that was dependent on lipid raft location.
However, it is possible that soluble PrP can still bind extracellularly to the EAATs,
therefore never necessitating membrane localization to control transport. EAAT
interaction with intracellular proteins in the lipid raft have been identified: GTRAP 41 and
GTRAP 48 increases EAAT4 activity (Jackson et al., 2001) while GTRAP 3-18
decreases EAAT 3 activity (Lin et al., 2001). All three EAAT interacting proteins, the
only ones identified so far, act on neuronal EAATs through binding to the C-terminal
intracellular domains. It is possible that PrP is an astrocytic EAAT interacting protein
that decreases EAAT activity through interaction with the extracellular domains on
EAAT1 and/or EAAT2.
The EAATs are also subject to regulation through membrane trafficking and it is
possible that PrP exerts its influence on EAAT activity by affecting local concentrations
of EAAT protein on the membrane. Pre-incubation with L-glutamate has been shown to
alter membrane expression of EAAT1, which was prevented by actin disrupting agents
(Duan et al., 1999). It has been suggested that EAAT2 can be rapidly internalized by
clathrin-mediated endocytosis (Zhou and Sutherland, 2004; Susarla and Robinson,
2008). Alterations in membrane levels of EAAT1/2 may be a mechanism to maintain
local glutamate concentrations but would require an extracellular sensor (Chaudhry et
al., 1995). As an extracellular protein, PrP could act as a sensor and mediate the
internalization of astrocytic L-glutamate transporters in response to L-glutamate
concentration. Previous studies have suggested that PrP can act as a stress sensor for
hydrogen peroxide (Krebs et al., 2007) and copper (Rachidi et al., 2003). In our studies,
EAAT activity was measured by exposing WT and PrP KO astrocytes to varying
concentrations of D-aspartate. We observed substrate concentration dependant
differences in EAAT activity between PrP KO and WT astrocytes. Interestingly,
evidence suggests PrP is also internalized via clathrin-mediated endocytosis, which is
unusual for a GPI-anchored protein lacking an intracellular sequence necessary for
interaction with endocytic adaptor proteins. It is possible that internalization of PrP
requires its interaction with an integral membrane protein that contains a localization
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sequence for clathrin-mediated endocytosis. Thus, PrP interaction with EAAT 1 and/or
EAAT 2 may serve to maintain a local glutamate concentration at the synapse.
EAAT internalization through clathrin-mediated endocytosis was specifically
studied on EAAT 2 and whether a similar action of activity dependent internalization of
EAAT1 is unknown. In our studies, the transporter subtype responsible for the majority
of transport was EAAT1, which was most likely a result of EAAT1 being highly
expressed in our cultures. Despite efforts to increase EAAT2 expression through
dbcAMP treatment and co-culture with neurons, levels of EAAT2 expression were
typically 10 fold lower than EAAT2 in all cultures. Thus, the contribution of EAAT2 to
transport in WT and PrP KO astrocytes was overshadowed by the high contribution of
EAAT1. We hypothesized that the influence of PrP on primary astrocyte L-glutamate
transport was through modulation of EAAT1 activity and it remains to be seen whether
similar modulation by PrP would act on EAAT2 and EAAT3 in the synapse. Future
studies looking at transport in synaptosomes, whose pharmacology profile is EAAT2
dominant, will address this issue.
However, if PrP specifically acted on EAAT1 to decrease L-glutamate transport,
its contribution to regulating L-glutamate concentrations in vivo would not be
insignificant. EAAT1 is expressed throughout the brain though, in contrast to primary
astrocytes in vitro, its expression is lower than EAAT2 whose expression dominates in
all areas of the brain except the cerebellum (Danbolt, 2001). The assumption that
EAAT2 is the most relevant L-glutamate transporter in vivo is most likely due to its high
expression. For example, quantitative immunoblotting demonstrated that in the
hippocampus, EAAT2 is four times higher than EAAT1 (Lehre and Danbolt, 1998). Over
90% EAAT2 activity is immunoprecipitated from crude forebrain extracts of reconstituted
activity (Haugeto et al., 1996) and the pharmacology profile of synaptosomes is mainly
EAAT2 (Koch et al., 1999b). Thus, analogous to what we observed in our primary
astrocyte cultures, expression differences of EAAT1 and EAAT2 might hide functional
contributions to overall L-glutamate transport. Understanding the contribution of other
transporters to maintenance of L-glutamate homeostasis is overshadowed by EAAT2
dominant expression. Interestingly, pharmacological inactivation of EAAT2 did not lead
to widespread neuronal death as expected, suggesting that other L-glutamate
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transporters such as EAAT3 and EAAT 1 can be rapidly mobilized to clear L-glutamate
(Selkirk et al., 2005).
The importance of EAAT1 is poorly understood in vivo. EAAT1 is the dominant
transporter expressed during development in all regions of the brain and its expression
remains throughout adulthood. EAAT1 is the primary transporter expressed by
Bergman glia in the cerebellum and EAAT1 knockout mice suffer from cerebellar ataxia.
Interestingly, dysfunction in EAAT1 is implicated in schizophrenia (Karlsson et al.,
2009), a disease in which a hypothesized mechanism is decreased glutamate signaling
(Miyamoto et al., 2005). PrP KO mice suffer from abnormalities that may be related to
dampened L-glutamatergic neurotransmission including reduced synaptic transmission,
long term potentiation and poor behavior in learning and memory tasks (Criado et al.,
2005). These observations may be the result of premature clearance of glutamate by
overactive astrocytic EAATs.
Does abnormal L-glutamate transport contribute to the synaptic dysfunction
observed in transmissible spongiform encephalopathies (TSEs)? TSEs are fatal
neurodegenerative diseases. Several mammalian TSE strains exist, including bovine
spongiform encephalopathy or “mad cow disease” in cattle, scrapie in sheep and goats,
chronic wasting disease in deer and elk and Gerstmann Sträussler Scheinker
syndrome, familial Creutzfeldt-Jacob Disease (CJD), fatal familial insomnia, variant
CJD, and kuru in humans. Notably, the species barrier usually restricts transmission of
TSE diseases from one species to another, but as evident with BSE transmission to
humans, is possible. Fortunately, the difficulty in crossing the species barrier as well as
increased surveillance in human consumed game and livestock has rendered human
transmission low; the incidence of disease is one or two cases per million humans.
Nevertheless, the spread of disease within an infected herd and threat of human
infection has consequently made an enormous economic impact on the livestock and
hunting industries.
TSE strains are unique in the targeted species, incubation time, clinical
presentation and tissues affected. However, they share common histopathological
characteristics. Disease manifests itself as grey matter spongiform vacuolation,
neuronal dropout and gliosis, usually colocalizing with PrPres. PrPres is conformationally
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distinct from PrP in that it is β-sheet rich and prone to aggregation. PrPres accumulates
at the cell surface in intracellular vesicles or as diffuse extracellular deposits (Caughey
et al., 2009). Typically, TSEs are characterized by a long incubation time in which most
symptoms, in relation to the incubation period, shortly precede death. Spongiform
vacuolation may be an early morphological marker as neurons are not lost yet but
vacuoles are formed within them (Moreno and Mallucci, 2010). In mouse models,
synaptic pathology represents one of the earliest changes seen in the disease (Clinton
et al., 1993; Fuhrmann et al., 2007; Mallucci et al., 2007) and results in reduced
synaptic responses and behavioral deficits related to spatial learning (Mallucci et al.,
2007). The disease progresses into ataxia and wasting. In humans, clinical symptoms
are characterized by cognitive decline, dementia and cerebellar ataxia (Aguzzi et al.,
2008).
The causes of synaptic pathology in TSEs are unknown but abnormal EAAT
activity could be a contributing factor. The direct and indirect vulnerability of neurons to
PrPres induced damage demonstrates that the disease takes advantage of the
relationship between neurons and astrocytes. Mice expressing PrP only on neurons are
susceptible to TSE infection (Race et al., 1995), suggesting that PrP expression on nonneuronal cells is not necessary for disease. However, neurons secrete soluble factors
that affect EAAT expression (Gegelashvili et al., 1997; Swanson et al., 1997; Yang et
al., 2009) as well as present PrPres extracellularly which may cause compromised
astrocytic EAAT function. Interestingly, mice expressing PrP only on astrocytes are also
susceptible to TSE (Raeber et al., 1997), demonstrating that neuronal damage from
infection can come indirectly. Astrocytes are one of the earliest sites of PrPres
accumulation in the brain (Diedrich et al., 1991) and PrPres toxicity might also cause
disturbance in astrocytic EAAT activity, thereby perturbing synaptic L-glutamate
homeostasis. These abnormalities could precede the development of neuropathological
changes but affect more subtle phenotypes such as altered dendritic spine morphology
(Fuhrmann et al., 2007) and depressed synaptic responses (Mallucci et al., 2007).
Gliosis in the terminal stages of disease may lead to reversal of glutamate uptake (Koch
et al., 1999a) in which the EAATs may act as a site of efflux for cellular L-glutamate.
Interestingly, increased EAAT1 expression was observed in microglia of patients with
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CJD and FFI who had long survival periods suggesting that, though not sufficient to
prevent neurological deterioration, microglial expression of EAAT1 might be
neuroprotective. If EAAT dysfunction plays a role in pathology of TSE diseases several
questions would have to be addressed, such as the duration of exposure to TSE,
whether PrPres accumulation is necessary and whether possible dysfunction is great
enough to lead to neuronal damage.
The function of PrP may be multidimensional, converging on a role maintaining
synaptic specificity in which activity dependent events are targeted towards appropriate
neurons and receptors, limiting spillover, excessive activation or premature signal
termination. The importance of EAATs in controlling glutamate signaling is region
dependent and thus, PrP’s influence may be most critical in areas where astrocytes
tightly ensheath nerve terminals. Perhaps in other areas where termination of signal
operates through diffusion, PrP affects L-glutamate receptor distribution or activation.
The symptoms and pathology of TSE infection may take advantage of the role of PrP in
the glutamatergic system starting with a pre-clinical stage characterized by low-level
synaptic dysfunction and ending with a clinical stage that may be a result of
excitotoxicity and transporter reversal. Through modulation of EAAT activity and
glutamate receptor dynamics, the function of PrP may be to maintain an optimal level of
L-glutamate in the synaptic cleft during all phases of neuronal signaling.
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